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1.	ABSTRACT
Background: Chronic exposure to glucocorticoids leads to Cushing’s syndrome (CS) with its metabolic consequences. AMPK is involved in many metabolic processes.
Cortisol circulates largely bound to binding proteins, with the smaller amount of unbound hormone responsible for its metabolic effects. In acute illness binding proteins fall and total cortisol (TC) no longer reflects free cortisol (FC) levels. 
Hypothesis: I hypothesized that 1) AMPK has an important role in metabolic consequences of CS and 2) FC, as compared to TC, offers a better reflection of the degree of stress and is a better prognostic measure in acute illness. 
Methods: Wistar rats were implanted with corticosterone or placebo pellets and tissues collected. Adipose tissue of patients with CS and controls was sampled and AMPK measured by AMPK assay. Experiments were confirmed in vitro. 
FC was measured by a specially developed assay in two prospective clinical studies in acutely ill patients. 
Results: In the animal model, AMPK was decreased in adipose tissue and heart, and increased in liver and hypothalamus. This was confirmed in vitro in the respective cell lines. In visceral adipose tissue of patients with CS, AMPK was lower compared to controls. 
During acute illness, the increase above basal FC was higher than the increase in TC and fell more markedly. After ACTH stimulation, TC increased to a similar and FC to a lesser extent as in major stress. The value of cortisol in predicting outcome was higher as compared to routinely measured parameters. The predictive value of FC was not superior to TC. 
Conclusion: Glucocorticoid-induced changes in AMPK constitute a novel mechanism possibly explaining some of the metabolic consequences of CS. 
The more pronounced increase in FC seen during stress as compared to the ACTH test suggests that this test does not adequately anticipate FC levels needed during severe stress. The prognostic accuracy of FC is not superior to TC. 
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2	BACKGROUND
2.1.	AMPK 
2.11.1.	Structure of AMPK
AMPK is a heterotrimeric enzyme composed of an α catalytic subunit and two regulatory subunits: β and . Each subunit exists as two or three different isoforms which are encoded by different genes (α1, α2, β1, β2, 1, 2 and 3) allowing for twelve different combinations. All the combinations exist although α1β11 is the most common in the majority of tissues. The different isoforms have different dependence on AMP and different distribution, not only amongst tissues but also in the cells themselves, where α2 seems to be more prominent in the nucleus and α1 in the cytoplasm (1, 2). The  subunit of AMPK contains 3 AMP binding sites. These are formed at the interface of its 2 pairs of CBS domains, called Bateman domains. Two of these binding sites can bind either AMP or ATP, whereas a third site contains a tightly bound AMP that does not exchange (3). When AMPK is inactive under physiological conditions, it binds two ATP and one AMP molecules while in low energy states it binds three AMP molecules (Figure 1). It is now proposed that the interaction of the catalytically active kinase domain (α) with the AMP-bound  subunit protects the phosphorylated Thr172 residue located at the α subunit from dephosphorylation 


Figure 1: The  subunit of AMPK containing 3 AMP binding sites. 











2.11.2.	Regulation of AMPK
Three different pathways activate AMPK through high AMP levels, the most important one being the fact that AMP binding makes AMPK a more suitable substrate for the upstream kinase LKB1. LKB1, which is a tumour suppressor kinase, phosphorylates the α subunit of AMPK at the threonine residue 172 (Thr172) thereby activating the molecule (4). Other upstream kinases activating AMPK are calmodulin kinase kinase (CaMKK) (5) and the recently described kinases transforming growth factor- activated kinase (TAK1) and ataxia telangiectasia mutated (ATM). Secondly, a rise in the AMP:ATP ratio activates AMPK allosterically (Figure 2). 




Figure 2: Allosteric activation of AMPK caused by AMP binding. Both the α and the  subunits participate in the allosteric activation of AMPK by AMP.


Thirdly, AMP binding to AMPK inhibits AMPK dephosphorylation at the Thr172 site by protein phosphatases. 
The fact that AMPK is activated by three distinct pathways indicates the exquisite sensitivity of the system and the importance of its regulation. It is an example of multi-step sensitivity, where a signal molecule, AMP in this case, affects more than one step in an enzymatic cascade. The sensitivity of AMPK is further increased by the recent discovery that the two Bateman domains of the  subunit bind AMP cooperatively. On the whole, it is believed that this ultrasensitivity is important for AMPK to maintain cellular energy levels within narrow limits.
AMPK can also be activated by other cytological stresses such as hyperosmotic stress, lack of nutrients, hypoxia, the hormones leptin and adiponectin and certain drugs such as phenformin or metformin (Table 1). 

Table 1 Factors that regulate AMPK
Type of treatment	Treatment
Respiratory chain inhibitors	Nitric oxide
Environmental stresses	Heat shock
	Oxidative stress
	Osmotic stress
Metabolic stresses	Ischaemia
	Hypoxia
	Low glucose
	Exercise (muscle)
Hormones and cytokines	Muscular contractionLeptinAdiponectinGhrelinInsulinGLP-1CannabinoidsIL-6
Biguanide drugs	Metformin
	Phenformin
Thiazolidinedione drugs	RosiglitazonePioglitazone















Furthermore, it has recently been shown that AMPK can directly be regulated by glycogen and may act as a glycogen sensor (6). The 1-6 linkage brachned forms of glycogen allosterically inhibit AMPK more potently than the linear 1-4 linked forms (6). In addition to the allosteric effect, the branched glycogen also inhibits LKB1- or CaMKK2-induced Thr172 phosphorylation, while dephosphorylation is not affected by glycogen. A new model of AMPK regulation, which is independent of AMP, has recently been identified. It has been shown that cell-death-inducing like effector (Cidea) forms a complex with the -subunit of AMPK, eliciting an ubiquination-mediated degradation of AMPK (7). The regulation of AMPK is summarized in Figure 3. 
Figure 3: Stimulators (red) and inhibitors (blue) of AMPK





α




When activated, AMPK stimulates catabolic pathways and inhibits anabolic pathways 
to restore the energy status in the cell (8) (Figure 4).
AMPK plays a role in the regulation on fatty acids and cholesterol metabolism. In vitro, it inactivates 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and acetyl CoA carboxylase (ACC), key enzymes in the regulation of de novo synthesis of cholesterol and fatty acids respectively.



Figure 4: Some of the effects of AMPK (http://www.svimr.unimelb.edu.au/amppkintro.htm (​http:​/​​/​www.svimr.unimelb.edu.au​/​amppkintro.htm​))


2.11.3.	Effects of AMPK activation in different organs
2.11.3.1.	 Role of AMPK in adipose tissue metabolism
Adipose tissue has been considered for years as an energy storage organ while in the last decades it has increasingly been viewed as an active endocrine organ, which by secreting several proteins, known as adipokines, contributes to the regulation of the whole body metabolism. During fasting, lipolysis is activated in adipose tissue in order to provide fatty acids and glycerol as fuels for peripheral tissues. Activation of AMPK in rodent adipocytes leads also to a decreased lipogenic flux and a decreased triglyceride synthesis (9). It also stimulates fatty acid oxidation. AMPK inhibits ACC in vivo and in vitro (9, 10) and as in the liver it also inhibits the expression of lipogenic genes (11).  
However, there are contradictory  studies concerning the effect of AMPK activation on lipolysis. There is evidence that AMPK activation, either with AICAR or with overexpression of a constitutively active AMPK isoform or with biguanide treatment, has an inhibitory effect on lipolysis (9, 10). While the study of Yin et al. (12) suggested a lipolytic action for AMPK Daval et al. also suggested that the lipolytic action of AMPK is via phosphorylation of HSL and, more importantly, occurs via inhibition of HSL transport to the lipid droplet (9). They also suggest that in conditions where lipolysis is activated, such as fasting and exercise, AMPK is activated and for a feedback mechanism this activation translates into inhibition of adipose lipolysis, which is an energy consuming process for the adipocyte (9). Contradictory are also the studies related to the effect of AMPK on glucose transport in adipose tissue. Two studies by Salt et al. (13) and by Wu et al. (14) suggested that AMPK stimulates glucose uptake in adipocytes, while a third study by Sakoda et al. (15) showed that  AICAR stimulated glucose uptake was independent of AMPK activation. In conclusion, AMPK activation in adipose tissue, under conditions such as exercise, fasting or after stimulation with leptin, adiponectin or biguanides, is generally considered to decrease lipogenesis, triglyceride synthesis and lipolysis, and increases fatty acid oxidation and glucose transport, contributing therefore to  improved insulin sensitivity.

2.11.3.2.	 Role of AMPK in liver metabolism
The liver is the major site for storage and release of carbohydrates and for fatty acid synthesis. It responds to fasting with increased glucose output and increased fatty oxidation while in postprandial conditions liver glucose uptake increases with consequent glycogen and triglyceride synthesis (16). AMPK regulates liver lipid and glucose homeostasis via phosphorylation of multiple enzymes (e.g. acetyl-CoAcarboxylase (ACC), 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), glycerol-3-phosphate acyltransferase (GPAT)) and influences the expression of genes involved in gluconeogenic, glycolytic and lipogenic processes and of their upstream regulators (e.g. liver-type pyruvate kinase (L-PK), fatty acid synthase (FAS), Spot14 and ACC, sterol regulatory element-binding protein-1c (SREBP-1c), carbohydrate response element-binding protein (ChREBP), nuclear hormone receptor (HNF4), phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase), transducer of regulated CREB activity (TORC2) etc) (17-19) (for an excellent review on the topic see (20)). Therefore, AMPK activation in the liver results in inhibition of gluconeogenesis and glycolysis, fatty acid, triglyceride and cholesterol synthesis and stimulation of fatty acid oxidation. Changes in hepatic metabolism are certainly present in obesity and type 2 diabetes (elevated glucose production by the liver is the major cause of fasting hyperglycemia in type 2 diabetes) (21), and it is possible that AMPK activation, by decreasing gluconeogenesis and cholesterol synthesis, would be beneficial in these patients. Nevertheless, caution is advisable because AMPK activation by increasing fatty acid oxidation and ketogenesis might lead to ketoacidosis, and by inhibiting protein synthesis might lead to a negative nitrogen balance together with enhanced urea synthesis (20). 
It has recently been shown that an increase in free fatty acids leads to fatty acid esterification, an energy consuming process, and this can increase the cellular AMP:ATP ratio and therefore AMPK activity (22). 

2.11.3.3.	 Role of AMPK in skeletal muscle metabolism
Skeletal muscle is the major site of glucose uptake (23), a process that is mainly stimulated by insulin but also by other alternative pathways. Exercise stimulates glucose uptake in the skeletal muscle independently of the insulin pathway and AMPK appears to be the mediator of this effect, at least partially, and at least in  glycolytic muscle. These conclusions are derived from studies in which in vivo AICAR treatment stimulated glucose uptake (24); the effect was not inhibited by inhibition of the insulin-dependent PI3K pathway and was additive to insulin-stimulated glucose uptake (25, 26). AICAR also stimulates the glucose transporter GLUT4 expression, most probably via increased nuclear content and increased binding to DNA of two transcription factors, myocyte enhancer factor-2 (MEF-2) and GLUT4 enhancer factor (GEF) (27), both required for GLUT4 expression (28). It also enhances GLUT4 translocation in rat skeletal muscles (26). Akt substrate of 160kDa (AS160) is involved in GLUT4 translocation and appears to be one of the downstream targets of AMPK in mediating glucose uptake (29). Chronic AMPK activation increases also hexokinase II (HKII) expression (30) and inactivates glycogen synthase (31). As previously mentioned, the effect of AMPK is fibre dependent and is different upon resistance or endurance exercise. AMPK stimulates glucose uptake and GLUT4 expression/transport in fast-twitch (glycolytic) white skeletal muscle but not in slow-twitch (oxidative) dark muscle (32, 33). The effects induced by AMPK activation, such as increased glucose uptake, glucose and fatty acid oxidation, GLUT 4 and HKII expression are similar to those produced by endurance exercise (e.g. distance running) (1), while resistance exercise (e.g. weight lifting) induces changes such as increased glycogenolysis and glycolysis via AMPK independent mechanisms (1). AMPK in muscle is activated during exercise, probably as a result of the exercise induced increase in AMP:ATP ratio and IL-6 release, a cytokine, which activates AMPK in isolated rat muscles (34). AMPK activation in endurance exercise could also explain the lack of muscle hypertrophy in this type of exercise in contrast to the resistance one. This is possibly due to AMPK inhibiting the mTOR pathway, which is stimulated by growth factors and amino-acids, and stimulates protein synthesis and hence cell growth and hypertrophy (1). AMPK is also probably the mediator of upregulation of mitochondrial biogenesis during endurance exercise. PPAR coactivator-1 (PGC-1), a transcriptional coactivator, is a key regulator of mitochondrial biogenesis (35). PGC-1 expression is upregulated both by endurance exercise in vivo and by AICAR in vitro (36).
AMPK also regulates fatty acid oxidation in muscle. During exercise and muscle contraction, activated AMPK inhibits ACC to reduce malonyl CoA concentrations, thereby stimulating the entry of long-chain acyl-CoA into the mitochondria for  oxidation (24, 37). This results in lower lipid deposition in muscle and therefore is one of the components of the insulin-sensitising effect of AMPK. 
Studies with transgenic mice (i.e. AMPK 1 and 2 knockout mice, muscle specific overexpression of AMPK 2 dominant negative, skeletal muscle specific LKB1 knockout, AMPK 3 knockout, muscle specific overexpression of AMPK 3 and muscle specific overexpression of AMPK 3 R225Q mutant) (for detailed descriptions see (1, 38)) have provided further evidence for AMPK being the main mediator, although not the only one, of the adaptations (increased glucose uptake, fatty acid oxidation, inhibition of glycogen synthesis) of skeletal muscle in response to exercise. 

2.11.3.4.	 Role of AMPK in the hypothalamus
The role of AMPK in the regulation of body weight and energy homeostasis is not limited to its actions in the peripheral tissues. 
AMPK plays an important role in the regulation of body weight and energy homeostasis in the hypothalamus. AMPK is expressed in the neurons of the central nervous system (39). Recent studies (40-42) have demonstrated that AMPK activity in hypothalamic neurons is altered by various factors and mediates their feeding effects. Administration of the glucose antimetabolite 2-DG, mimicking hypoglycaemia, increases hypothalamic AMPK activity. Conversely, intracerebroventricular (icv) administration of glucose or restoration of food intake decreases hypothalamic AMPK activity (41). Hypothalamic AMPK activity is also altered by physiologic feeding regulators. Intracerebroventricular (icv) administration of the anorexigenic hormones such as insulin and leptin reduce AMPK activity, whereas the orexigenic ghrelin increases it (41, 42). Also cannabinoids and ghrelin have an effect on AMPK both in the hypothalamus as well as in peripheral tissues (43). The downstream pathways of AMPK in the hypothalamus are most probably the ACC-malonyl CoA-CPT1 pathway (44) and the mTOR pathway (45, 46). The activation of AMPK occurring during fasting or after icv AICAR administration results in ACC inactivation and lower levels of malonyl-CoA in neurons. Moreover, icv administration of C75, a fatty acid synthase inhibitor, reduced food intake, inhibiting the phosphorylation of neuronal AMPK and leading to a consequent decrease in phosphorylation of ACC with increased levels of malonyl-CoA. The mechanism underlying this action could involve an increase in CPT1 activity and inhibition of fatty acid synthase (FAS) (44). However, the mechanisms as to how AMPK in hypothalamic neurons affects feeding behaviour are as yet only partially understood. One suggested mechanism is that hypothalamic AMPK controls feeding behaviour through the regulation of the orexigenic neuropeptides Y (NPY) and AGRP expression (47, 48). 

2.11.3.5.	 Role of AMPK in the heart
Cardiovascular diseases are a common consequence of obesity and obese patients are often treated not only for their excessive body weight but also for all the related complications. In view of this and in view of the fact that AMPK is proposed as a possible target for obesity and diabetes treatments, it is important to know the role of AMPK in cardiac physiology and pathology (for an extensive review on the topic see (49)) in order to avoid possible side effects of possible future AMPK activators/inhibitors. AMPK is a key regulator of energy metabolism in the heart, too. The heart, which is an organ with high energy demand, utilises both fatty acids and glucose as energy resources. AMPK influences heart glucose metabolism targeting glucose transporters, phosphofructokinase-2, glycogen synthase, glycogen phosphorylase, p38 MAPK with an overall effect of stimulating glucose uptake, glycolysis, glycogenolysis, GLUT4 transport and decreasing glycogen synthesis. It also increases fatty acid supply, oxidation and uptake via lipoprotein lipase, CD36, ACC, malonyl CoA decarboxylase. Furthermore, similar to the situation in other organs, AMPK decreases protein synthesis via eEF2 kinase, mTOR and TSC2 (49). AMPK is rapidly activated during ischaemia. There is no general agreement as to whether this increase in AMPK activity is beneficial, even though the majority of the studies would suggest so because AMPK activation would generate more ATP and therefore protect cardiac tissues. On the other hand, AMPK activation would also stimulate fatty acid oxidation which in turn would inhibit glucose oxidation and result in a reduction in cardiac efficiency (49). The pro-apoptotic effect of AMPK could also be harmful for the ischaemic heart. Another controversial area is  the putative role of AMPK in cardiac hypertrophy, with both activating and inactivating mutations of AMPK resulting in marked hypertrophy (49). 

2.11.4.	AMPK in obesity
The majority of the research studies are performed on animals, and as usual it is important to establish the relevance these conclusions would have on human physiology/pathology. In contrast to the numerous studies present on AMPK in rodents, studies regarding AMPK activity in human pathology are, for understandable reasons, much more limited. Skeletal muscle AMPK activity has been analysed in a limited number of obese vs. lean subjects, in obese diabetic vs. obese non-diabetic patients and in healthy subjects before and after exercise. Obesity in humans is associated with leptin resistance and lipid accumulation (the result of increased total palmitate uptake) in skeletal muscle. AMPK plays a major role in skeletal muscle metabolism regulation, and muscle AMPK activation by adiponectin or AICAR in obese rodents stimulates FA oxidation. It can therefore be hypothesised that pharmacological activation of AMPK might be of therapeutic benefit in human obesity. 
Nevertheless, AMPK is not down-regulated in human skeletal muscle of obese females (50), and AMPK activity and isoform protein expression are similar in the muscle of obese subjects with and without type 2 diabetes (51). These data suggest that impaired insulin action on glycogen synthesis and lipid oxidation in the skeletal muscle of these patients is unlikely to involve changes in AMPK expression and activity. However, AICAR treatment of muscle biopsies stimulated AMPK2 activity and FA oxidation, suggesting that AMPK activation above basal levels may still be a valid therapeutic approach. 


A beneficial potential of AMPK activation in muscle is also shown by the study from Bluher et al., who showed that acute intensive exercise (3h) increased AMPK and ACC phosphorylation altogether with an increase in expression of the adiponectin receptor in the skeletal muscle of five healthy females (52). Conversely, Roepstorff et al. (53) showed that AMPK activation in muscle is sex-dependent: 90 minutes of exercise activated AMPK in skeletal muscle of healthy male volunteers but not in females, suggesting that fat oxidation is independent of AMPK in women. This opens the question towards a role for oestradiol influence on AMPK activity. 

2.11.5.	AMPK as an overall metabolic regulator
In conclusion, AMPK, as is emerging from the numerous studies and the ever-growing research in this area, is a key regulatory enzyme of cell and whole body metabolism. It influences cell metabolism in a way that favours insulin sensitivity and to maintain a favourable body energy homeostasis. It is the mediator of the metabolic effects of many of the known hormones /nutrients and drugs and therefore changes in hormone levels, present in obesity, type 2 diabetes and the metabolic syndrome that are reflected in alteration of AMPK activity in peripheral and central tissues. In this way, not only could changes in AMPK  be implicated in the pathogenesis of insulin resistant states, but AMPK could also constitute a target for new treatments of these conditions. Nevertheless, new AMPK modulators should be considered carefully  because general AMP activation might result in undesiderable effects (i.e. an appetite stimulating effect and -cell inhibition), and tissue-specific tissue  AMPK modulators are desirable.

2.2.	 Cushing’s syndrome
Cushing’s syndrome results from chronic exposure to excess glucocorticoids, either produced by the adrenal cortex or given exogenously. Data from United Kingdom and Icelandic studies (54-56) suggest that 0.5-0.9% of the population is receiving chronic (>3 months) glucocorticoid treatment at any one time. Therefore, together with patients with pituitary, adrenal or ectopic Cushing’s syndrome, more than half a million people are currently exposed to long-term glucocorticoid effects in the United Kingdom. The chronic high levels of glucocorticoids induce central obesity, systemic arterial hypertension, impaired glucose tolerance and dyslipidaemia, ultimately leading to many of the manifestations of the metabolic syndrome (57); such manifestations contribute to the increased cardiovascular risk observed in patients with Cushing’s syndrome, altering life expectancy and life quality, and may persist even when the excess glucocorticoid exposure is normalised (58, 59). Obesity in Cushing’s syndrome develops in part by increased food consumption (60), and is characterised by increased body weight, reduced lean mass and a characteristically distributed fat accumulation with a shift from the more inert subcutaneous to accumulation of the metabolically more active visceral fat (61, 62). In addition to this effect on fat distribution, glucocorticoids regulate the differentiation of adipose stromal cells and affect the function of adipocytes leading to the accumulation of lipid (63). Apart from fat tissue, glucocorticoids cause abnormal metabolism in the liver, with insulin resistance and hepatic steatosis (62), in skeletal muscle with accelerated protein breakdown, in bone with increased bone loss with increased risk for osteoporotic fracture, and in the heart (hypertension and left ventricular hypertrophy, atherosclerosis and myocardial ischaemia). The myocardial abnormalities are not fully explicable by the secondary changes due to insulin resistance and hypertension, and suggest an additional direct effect of excess cortisol on the myocardium (64, 65). 

2.3.	Endocannabinoids
Cannabinoids stimulate appetite in humans (66), and this effect has now been reproduced using the endogenous cannabinoids anandamide (AEA) and sn-2 arachidonoylglycerol (2-AG) (review (67)). The CB1 antagonist rimonabant (SR141716) inhibits food intake, and phase III clinical trials have shown sustained effects on weight loss in humans through effects on glucose and fat metabolism (68-70). The effect of endocannabinoids on food intake is mediated by the hypothalamus where both CB1 and endocannabinoids are present at a high concentration, and which contains sites sensitive to the hyperphagic actions of cannabinoids. Recently, it has been shown that glucocorticoids in the hypothalamus can act by activating a G-protein-dependent signalling mechanism that leads to a retrograde release of endocannabinoids and results in the suppression of synaptic glutamate release (71). Biochemical analysis of rat hypothalamic slices treated with dexamethasone revealed a glucocorticoid-induced rapid increase in the levels of the endocannabinoid anandamide and 2-arachidonoylglycerol (72). This could be a new explanation by which glucocorticoid might act to increase food intake (73).

2.4.	Corticosteroids in acute illness
High cortisol levels reflect a higher degree of stress (74). The effects of cortisol are directed towards the acute provision of energy, protection against excessive inflammation and improvement in haemodynamic status (75, 76). Therefore, appropriate activation of the hypothalamo-pituitary adrenal axis during illness is essential for survival, and parallels the degree of stress. Several studies have shown a positive correlation between serum total cortisol and severity of critical illness as well as the risk of death (77-83). 
Cortisol circulates in blood largely bound to corticosteroid-binding protein and albumin (84), with the much smaller amount of unbound hormone responsible for its metabolic effects (84-87). In general, it is assumed that the biologically active level of cortisol to which tissues are exposed is free cortisol (FC). Routinely available assays of adrenal function measure serum total cortisol (TC) and not the biologically active FC, but it is usually considered that TC broadly correlates with the biologically active free fraction. However, the activation of the hypothalamo-pituitary-adrenal axis in critically ill patients is characterised by an increase in FC levels and a possibly smaller increase in TC levels (88), mainly because it has been shown that in critically ill patients there is a fall in binding proteins and TC levels no longer accurately reflect the free fraction (88, 89). The importance of this fall in corticosteroid binding protein (CBG) on measured serum TC concentrations in acute stress has recently been recognised (90), and the authors of this study recommended the use of a calculated correction factor, the free cortisol index, defined as the serum cortisol concentration divided by the CBG concentration, as a surrogate marker to better define glucocorticoid secretion (90). However, the FC index does not take into account the effect of hypoalbuminaemia, which often accompanies low serum concentrations of CBG, and thus does not measure the actual serum FC concentration (89). 
Serum FC concentrations, as compared with serum TC concentrations, might offer a better reflection of the degree of stress and the subsequent activation of the hypothalamo-pituitary-adrenal axis in critically ill patients (88). Whether FC concentrations are better correlated with outcome such as death or treatment failure remains an open question. 

Previous studies have also demonstrated that, under the most stressful conditions, TC levels in response to major stress are mirrored by similar changes in the response to a pharmacological dose of adrenocorticotrophin (ACTH) (91). It has therefore been assumed that responsivity to the ACTH stimulation test will reflect the pituitary-adrenal response to surgery, trauma or other types of stress, and can be used as a surrogate to decide on the appropriateness of corticosteroid replacement therapy in surgery or acute illness (92), in the absence of recent pituitary surgery (93). 

3	AIMS OF THE STUDIES
3.1.	 Project A: Effect of corticosteroids on AMPK 
Both AMPK and corticosteroids play an important role in a number of metabolic processes, and I hypothesised that AMPK is regulated (probably in a tissue specific manner, similar to other hormones) by glucocorticoids. I have studied whether corticosteroids modulate AMPK activity using in vivo and in vitro methods: (i) a Cushing’s animal model; (ii) cell lines derived from the hypothalamus and the liver, (iii) freshly cultured human adipose cells, and iv) human visceral adipose tissue sampled from patients with Cushing’s syndrome as well as from controls undergoing non-endocrine-related perirenal operations. The in vitro studies were done to study whether the observed in vivo treatment effects are of a direct or indirect nature. 

3.2.	Project B: Free and total cortisol in acute illness
A novel serum FC assay has been developed. This assay has been validated  in two different studies. First, I aimed to compare total and free fractions of cortisol in subjects with increasing levels of stress and to assess whether the responsivity to a standard dynamic test of adrenal function does indeed reflect the adrenal response to surgical stress. 
Second, I aimed to evaluate the prognostic value of total and free cortisol levels, measured on admission, in the prediction of severity of disease and outcome in a well-defined cohort of patients with pneumonia, and to compare the prognostic value of free and total cortisol concentrations. 



4	MATERIALS AND METHODS
4.1.	In vivo experimental setup 
Rat experiment (performed in Hungary by Dr. Csaba Fekete and co-workers): The experiments were carried out on adult, male Wistar rats weighing between 220-250g. The animals were housed individually in cages under standard environmental conditions (light between 0600-1800h, temperature 221C, rat chow and water ad libitum). All experimental protocols were reviewed and approved by the Animal Welfare Committee at the Institute of Experimental Medicine, Hungarian Academy of Sciences. The animals were divided into the following three groups (n=8 in group a), and n=6 in groups b) and c)): 
a)	 Animals were adrenalectomised bilaterally under xilazine-ketamine anaesthesia. At the same time corticosterone pellets were implanted under the skin of each animal (94). The pellets were made using commercially available moulds, as previously described (94). Each pellet contained 100mg of corticosterone. After surgery, animals were provided with a bottle of 0.5% sodium chloride (NaCl) and a second bottle containing 30% sucrose to drink ad libitum until day 14, when they were sacrificed (94, 95). 
b)	 Animals were sham-adrenalectomised bilaterally and implanted with placebo pellets (containing cholesterol instead of corticosterone). Animals were offered 0.5% NaCl and 30% sucrose to drink ad libitum for 14 days, when they were killed.
c)	 Animals were sham-adrenalectomised bilaterally and implanted with placebo (containing cholesterol only) pellets drinking only 0.5% NaCl, without sucrose, for 14 days, when they were killed.
We used two control groups in the experiment: corticosteroid treatment in rats without sucrose administration results in marked stress and catabolism with only limited features of the metabolic syndrome and therefore does not provide a good model for human Cushing’s syndrome (94). Corticosterone-implanted rats were therefore provided with a sucrose solution to drink, and cholesterol-implanted rats were used with similar sucrose solution available, as the principal control for corticosterone administration. We also used saline drinking animals as the appropriate control group for the possible inhibitory influence of sucrose on tissue AMPK activity. 
In all animals, daily chow and sucrose intake was assessed and weight was measured. On day 14, when the animals were killed, blood samples for plasma corticosterone, adrenocorticotrophin (ACTH), insulin, leptin, ghrelin, adiponectin, glucose and triglycerides were taken. Samples of tissues (i.e. hypothalamus, liver, heart, visceral and subcutaneous adipose tissue, brown adipose tissue, dark muscle (i.e. soleus muscle), white muscle, and heart) were immediately frozen on powdered dry ice and stored at -80°C. The brain was dissected and the hypothalamus removed as a 2 mm thick coronal section from -2 to -4 from the Bregma, and from the supraoptic decussation to the dorsal end of the lower part of the third ventricle. The weight of the visceral (i.e. mesenteric, perirenal and epididymal fat) and subcutaneous (i.e. inguinal fat) was measured. 

Human tissue (human tissue kindly provided by Prof. Boscaro and co-workers): 
Visceral adipose tissue was sampled during adrenal operations in 11 patients with Cushing’s syndrome and 4 patients with non-endocrine-related perirenal operations. In addition, samples of adipose tissue from 9 patients, who were having adrenal incidentalomas removed as a diagnostic procedure, were taken. All patients gave their written informed consent, which was approved by the local Institutional Review Board. 

4.2.	In vitro studies
4.2.1.	Cells
Primary hypothalamic neuronal cell cultures were performed by Prof. Francois Pralong, Lausanne, as described (96). Hypothalami were obtained from 18 days old rat fetuses, cells were dispersed mechanically and plated at a density of 500 live cells/mm2 in 6-well plates coated with 5μg/ml poly-D-lysine (Sigma), and grown in NeurobasalTMMedium with 0.04% B27 supplement (Gibco) containing 500μM glutamine and 25M glutamate (Sigma). Forty-eight hours after plating, 2M araC (cytosine -D-arabinofuranoside; Sigma) was added to prevent proliferation of non-neuronal cells. Half of the medium was then changed every fourth day, and all experiments were performed in three to four weeks old culture. Experiments were performed after 6h of starvation of the cells in DMEM (Gibco) at 5.5mM glucose with no FCS.

The human hepatoma HepG2 cells (kindly provided from Dr B. Khoo) were maintained in a humidified atmosphere of 95% air and 5% carbon dioxide at 37°C in a 1xDMEM medium containing L-Glutamine [Gibco; 31885-049], 1000mg/l glucose, pyruvate, 10% FCS (GIBCO; 10108-157) and 1% penicillin and streptomycin (Sigma; S9137) (1% P/S). The cells were grown on T75 flasks and passaged three times a week on a 1:3 split. Trypsin 2.5% [Gibco; 15090-046], was used to separate the cells from the base of the flasks [Orange scientific] after washing them with 0.01M phosphate-buffered saline (PBS) [Gibco; 10010-056].

Human mesenchymal stem cells (MSC) from bone marrow were a gift from Prof. I. Martin, University of Basel. Their differentiation and culture has been reported previously (97, 98). Briefly, bone marrow aspirates (20-40 ml) were obtained from donors (18-63 years) during routine orthopaedic surgical procedures. Nucleated cells were isolated from the aspirate by Ficoll density gradient centrifugation (Histopaque1, Sigma, Buochs, Switzerland). MSCs were thereafter selected within the nucleated cells in culture on the basis of adhesion and proliferation on the plastic surface. The cells were expanded in DMEM, supplemented with 10% fetal calf serum (FCS) and 5ng/ml basal fibroblast growth factor (bFGF, Invitrogen AG, Basel, Switzerland) until they reached confluence. Adipogenic differentiation was induced by adding DMEM (Lonza, Verviers, Belgium) supplemented with nutrient mixture F-12 (1.8 g/l glucose, Lonza), gentamycin (50µg/ml), L-ascorbic acid (100nM), biotin (8µg/ml), D-pantothenat (15mM), HEPES (15nM) and 3% FCS. 
The medium was changed every 3 days. After 15 to 18 days differentiation medium was removed by washing with PBS. Adipocytes were kept for 48h in basal medium before experiments. 
All cell treatments were done with dexamethasone 10-6M diluted in ethanol (98, 99). Appropriately diluted vehicle was used for control. 

4.2.2.	Cell culture
All procedures mentioned below except from the centrifuging were carried out under sterile conditions using a grade II cell culture hood. All volumes mentioned below are for T75 flasks, T150 flasks require the double of the volumes stated in these methods.
	The trypsin (2.5%) and the culture medium were put in the water bath at 37°C to avoid disturbing the cell culture temperature when added to the flasks
	The culture medium was removed from the flasks using a Pasteur pipette and the cells were washed with 5ml of PBS
	Two ml of trypsin 2.5% were added to each T75 flask and the flasks were put back in the incubator for 5min
	When the 5min had gone by, the cells should be detached and floating in the trypsin. They were resuspended in 5ml of media and transferred to a 15ml centrifuge tube. The cells were centrifuged for 2min at 2000rpm at room temperature.
	The supernatant was removed and the cell pellet was resuspended in 6ml of media. Cells were counted at this stage using a haemocytometer. To continue growing the cells, 2ml of this cell suspension were transferred to each new flask and 15ml of warm media were added to it. The flasks were put back in the incubator.

4.2.3.	Cell treatment and protein extraction
The cells were treated with either ethanol 10-4M (i.e. control) or dexamethasone 10-6M dissolved in ethanol for 6 to 24 hours for the first study. Dexamethasone was prepared as follows: 3.925mg were dissolved in 1ml of 99% ethanol (=10-2M concentration). From this solution, 20µl were diluted in 9980µl of medium (=2x10-5M concentration). 500µl of this was then put as a treatment in the Petri dishes (with 9500µl of medium in it), with an end concentration of 10-6M.  Dexamethasone was always prepared freshly and kept covered because it is light sensitive. 
All the following steps were carried out on ice to preserve the proteins as much as 
possible. After the required time for each experiment, the media was aspirated using a Pasteur pipette and each plate was washed with 5ml of ice cold PBS to remove any remnants of treatment drug. Subsequently, 0.5ml of ice cold lysis buffer was added to each plate and the plates were scraped. The lysate was transferred to a 1.5ml tube [Eppendorf; 0030 108.116] and centrifuged for 5min at 13000G at 4°C. The supernatant was then transferred to a new labelled 1.5ml tube and stored at -80°C or used immediately for analysis.

4.3.	BCA assay
BCA assays (BCA Protein Assay®, Pierce) were used to measure the amount of protein extracted from the cells. BCA protein assay reagent A [Pierce; 23223], reagent B [Pierce; 23224] and bovine serum albumin (BSA) 2mg/ml in cell lysis buffer were used to make up the standard dilutions. Ninety-six well cell culture plates were used to read the samples in the spectrophotometer. 
1ml of BSA was transferred from tube “A” to tube “B” and well mixed, then 1ml was transferred of this new solution from tube “B” to tube “C”, and so on until tube “G”. The concentration of each tube is half of the concentration in the tube labelled with the previous alphabetical letter. The tube labelled “Blank” only contains cell lysis buffer.
From each of these tubes, 25l were transferred to different wells in the 96 well plate. This was done in duplicates or triplicates.
25l of each unknown sample was transferred to different wells in the 96 well plate. This was done in duplicates or triplicates. Different dilutions were prepared to avoid having a sample concentration above 2mg/ml, in which case the absorbance results would be beyond those of the standard curve.
The BCA working solution was prepared by mixing 50 parts of BCA reagent A with 1 part of working reagent B. 200l of the working solution was added to each sample and to each standard and mix. The following formula was used to work out the volume required:
(number of samples + number of standards) x 3 x 200l
The plate was incubated at 37°C for 30min and the absorbance read in the spectrophotometer at 595nm.
The standard curve constructed on Microsoft Excel and the concentration of the samples was calculated using the standard’s curve equation. The readings that were above the absorbance result of the higher standard (2mg/ml in this case) were diluted and re-measured.
Once the sample concentrations were known, 100 to 300g of each sample was aliquoted for the AMPK assay and 10g for the Western blot. The aliquots and the rest of the samples were stored at -80°C.

4.4.	Western blot
Western blotting was performed running 10-20g protein on a 7.5 or 10% SDS-gel (BIO-RAD, UK) and transferring it to a PVDF membrane (Immobilon-P, pore size 0.45 μm; Millipore UK Limited, Watford). Membranes were incubated with the primary antibody anti-phospho acetyl-CoA carboxylase (ACC) (1:1000, Upstate) in 5% non-fat dry milk in Tris-buffered saline-Tween overnight at 4 ºC. Goat anti-rabbit 1:10000 [DAKO] antibody was used for secondary antibody. After stripping the membrane β-actin (primary monoclonal antibody 1:5000 [Abcam, Cambridge, UK], secondary goat anti-mouse antibody 1:10000 [DAKO]) antibodies were used to normalise for equal loading and densitometric readings of the resulting bands were evaluated using the Scientific Imaging system (Kodak, New Haven, USA).

4.5.	Immunoprecipitate kinase assay for AMPK 
Immunoprecipitate kinase assays for AMPK, and analysis of Western blots using anti-peptide antibodies, have been described previously (100). Briefly, tissue samples were homogenised in 800ml of tissue lysis buffer with Precellys 24 (Stretton Scientific Ltd, Stretton, UK) (speed 6500rpm, 2 cycles of 30seconds), in lysis buffer containing 50 mM Tris-HCl, 50mM NaF, 5mM Na pyrophosphate, 1mM EDTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 1mM DTT, 1mM benzamidine, 1mM phenylmethane sulfonyl fluoride (PMSF), 5μg/ml soybean trypsin inhibitor (SBTI) for hypothalamus tissue the same lysis buffer used for hypothalamic cell line was used, and the protein content was determined using BCA assay (BCA assay, Pierce, Rockford, USA). Cell proteins were collected as above. AMPK activity in the immune complex was determined by phosphorylation of SAMS (substrate for AMP-activated protein kinase, Upstate, Dundee, Scotland, sequence HMRSAMSGLHLVKRR), a synthetic peptide substrate of AMPK. 100 to 300μg protein was immunoprecipitated using Protein G beads (Amersham, Bucks, UK) (10μl/sample) and a mixture of α1 and α2 AMPK antibodies (Prof. Hardie, University of Dundee, Scotland) (2.5μg/sample of each) (100) (for immunoprecipitation protocol see Appendix). The immunoprecipitate was divided into 3 aliquots and two were assayed for AMPK activity with a reaction solution containing 0.1μCi of γ32P ATP, 0.1μl of 100mM cold ATP, 0.25μl 1M MgCl2, 10μl 1mM AMP and 10μl of SAMS 0.1mM (Upstate, Dundee, Scotland or from Pepceuticals, Nottingham, UK) and the third aliquot with the same mixture except Hepes-Brij buffer replaced SAMS. Therefore, the first two were positive samples where the kinase in the sample phosphorylates SAMS, while the third aliquot serves as negative control where no substrate (other than peptides within the immunoprecipitated sample) is present. The reaction was performed on a shaker for 20 minutes at 30ºC and samples were pipetted onto paper squares (P81, Upstate). The reaction was stopped by placing the paper squares into 1% orthophosphoric acid and after repeated rinsing the activity was counted using Easy-count protocol in a scintillation counter, Perkin-Elmer machine. For separate α1 and α2 AMPK activity determination, 600μg protein was used and immunoprecipitation was performed sequentially for α1 and α2 AMPK. AMPK activity was calculated using the difference of the counts between SAMS containing and SAMS negative samples and expressed as nmol of ATP incorporated per minute per mg sample peptide. 

4.6.	RT-PCR
Fat adipose tissues (100mg) were homogenised in 1ml of QIAzol reagent [Qiagen, Crawley, UK] and total RNA was purified according to the manufacture’s instructions [Qiagen]. Liver and heart tissues (30mg) were homogenized in 175µl of RNA Lysis Buffer [Promega, Southhampton, UK] and using the Promega SV isolation kit (Promega) which includes a DNase step. The quality and concentration of RNA were assessed at A 260nm/280nm and its integrity by gel electrophoresis. cDNA was synthesized from 1μg of RNA in a total volume of 25μl, using random primer [Roche, Burgess Hill, UK, 11034731001] and reverse transcriptase [Invitrogen, Paisley, UK, 28025-013].  Levels of gene expression were quantified using real-time PCR with the human and rat specific assay-by-design primer and probe sets by Applied Biosystems [ABI, Warrington, UK] and the ABI PRISM 7900 Sequence Detector System for SREBP-1c, FAS, PEPCK-1c and hormone sensitive lipase (HSL) and with rat specific primers for glucose 6 phosphatase (G6P), AMPK α1 and AMPK α2. Control reactions for RT (containing RNA but no RT enzyme) and PCR (containg PCR mixture but no cDNA) were run together with samples. All gene expression assays have FAM TM reporter dye at the 5’ end of the TaqMan® MGB probe (minor groove binder) and a non fluorescent quencher at the 3’ end of the probe. The TaqMan® MGB probes and primers have been premixed (20X) to a concentration of 18μM for each primer and 5 μM for the probe [ABI]. PCR was performed in a final volume of 10μl. All the reactions were obtained in a duplex PCR reaction with β-actin (β-ACTB) as endogenous control [VIC® MGB Probe, Applied Biosystems] at this conditions: 5μl TaqMan® Universal Master Mix [Applied Biosystems], 0.5μl 20X Assay Mix primer, 0.35μl 20X Assay Mix ACTB and 3.5μl TE. Reaction was run at 40 cycles at 50°C for 2min (stage 1), 95°C for 10min (stage 2) and at 95° for 15sec and 60° for 1min (stage 3). The data were analysed using the standard curve method. The relative quantities of target transcripts were calculated from triplicate samples after normalisation of the data against the housekeeping gene β-actin.

4.7.	Endocannabinoid content measurement (mass spectrophotometry performed by Prof.George Kunos and co-workers)
Chloroform extraction was performed and the samples dried under nitrogen. An extracted Blank containing the d4-AEA, but no tissue was included each time to check the background from solvents, and to determine if any apparent AEA, 2-AG, OEA, or other contaminants were present as a result of the extraction procedure. Tissue levels of anandamide, 2-AG and 1-AG were quantified by liquid chromatography/in-line mass spectrophotometry by collaborators, as described (101). The amount of anandamide and 2-AG in the samples was determined by using inverse linear regression of standard curves. Values are expressed as pmol per mg wet tissue. 

4.8.	Lipid staining (performed by Dr. Eivind Carlsen)
10μm sections of frozen liver samples were cut and stained with Oil-Red-O and with Mayer’s haematoxylin as counterstain. Staining of sections was scored for a) droplet distribution and b) for staining intensity in positive cells as follows: 
a) Distribution: universal (all or almost all cells positive) score 2; zonal (groups of cells with intervening negative areas) score 1; negative (only the odd cell or no cells positive) score 0
b) Staining intensity in positive cells: strong (mixture of large and small globules of fat per cell) score 2; weak (only small globules of fat) score 1. 
The analysis was done by adding the score of a) and b) together. 

4.9.	Basal and insulin-mediated glucose uptake
Basal and insulin-mediated glucose uptake was performed as described previously (102). On day 1, the differentiation medium of the human adipocytes was removed. Cells were washed three times in warm PBS and kept in DMEM-F-12 containing 5mM glucose and 3% FBS. Supplements were added on day 2. On day 3, at t=0 minutes, 100nM insulin was added to one half of the cells. At t=20 minutes, 1μC 2-deoxy-D-[3H(G)] deoxy-glucose (Perkin Elmer, Boston, MA) was added to all wells. After another 15 minutes, the cells were washed three times in ice-cold PBS and lysed in 0.1% sodium dodecisulfate (SDS). Radioactivity was measured in a scintillation counter.

4.10.	Hormone and biochemical measurements
Corticosterone and ACTH were measured as previously described (103). Insulin, leptin, total (both acylated and unacylated) ghrelin and adiponectin (Linco, Missouri, USA) and glucose, triglyceride and cholesterol (all Instrumental Laboratory, Lexington, USA) were measured using commercial assays. Albumin was measured by Hitachi 917 (Roche, Rotkreuz, Switzerland). CBG was measured by a radioimmunoassay (BioSource Europe, S.A., Nivelles, Belgium).

4.11.	Measurement of cortisol – human study
Serum TC was measured using a chemiluminescence immunoassay (Nichols Advantage, Nichols institute Diagnostics, San Juan Capistrano, CA) with a calculated sensitivity of 13.8 nmol/l. The intraassay coefficient of variance was 4.4% and the interassay coefficient of variance was 11.0%. 
Serum FC was measured in-house by a specially developed assay (Dr.  Ray Edwards, Netria). The fractions of free and bound cortisol in serum samples were first separated by equilibrium dialysis, followed by measurement of the concentration of the free fraction in the dialysate using an enzyme immunoassay (NETRIA®, London, UK). Dialysis was carried out using a membrane with a MWCO of 12-14,000 Daltons. 200μl of undiluted sample was pipetted directly into dialysis tubing (diameter approx. 6mm), sealed at one end, and placed into an outer chamber (diameter 12mm) containing 800μl of buffer solution pH 7.4 (1% hydrolysed gelatin in phosphate buffered saline [0.05M phosphate, 0.15M sodium chloride]). Dialysis chambers were gently rotated at 37°C overnight. Dialysate containing the free fraction was assayed by enzyme immunoassay. 

The calculated sensitivity of the enzyme immunoassay (96-well microtiter plates coated with anti-cortisol antiserum) was 0.4nmol/l (at 2.5 standard deviation from zero cortisol concentration). The inter-assay coefficient of variance (CV) was 3.5% at 2.1nmol/l, 6.8% at 24nmol/l and 10.0% at 52nmol/l. Intra-assay coefficient of variance was assessed by precision profile with the following CVs; 10% at 1nmol/l, 6% at 10nmol/l, 5% at 20nmol/l and 7% at 100nmol/l.
Relative potencies of cross-reacting steroids were measured as follows;
Corticosterone 9%
11-Deoxycortisol 2%
17- hydroxyprogesterone 1.4%
Prednisolone 53%
Cortisone 1.4%
11-Deoxycorticosterone 0.2%
Progesterone 0.1%
Dexamethasone, testosterone, 17- oestradiol, tetrahydrocortisol and cholesterol <0.1%. 
The assay was validated in 12 patients with confirmed adrenocortical insufficiency (TC 134.1±134 nmol/l). Free cortisol levels in these patients were 2.7±2.5 nmol/l, significantly lower as compared to free cortisol levels in  healthy controls 36.9±17.2 nmol/l (all P-values <0.001).


 Figure 5: Free cortisol measurement by equilibrium dialysis. The fractions of free and bound cortisol in serum samples are separated by equilibrium dialysis as follows: dialysis is carried out using a membrane with a MWCO of 12-14,000 Daltons. 200μl of undiluted sample is pipetted directly into dialysis tubing (diameter approx. 6 mm), sealed at one end, and placed into an outer chamber (diameter 12 mm) containing 800μl of buffer solution pH 7.4.


4.12.	Study settings and designs of the clinical studies for validation of free cortisol assay 
4.12.1.	 Free cortisol in increasing situations of stress
Peri- and post-operative basal cortisol levels reflect the degree of surgical stress (104, 105), with peak cortisol levels being achieved in the immediate post-operative period, around the time of extubation (106, 107). Serum TC levels after major surgery approach the levels during the acute phase of septic shock (80, 108, 109). In this context, major surgery can serve as a standardised model for studying acute and major stress. 
Sixty-four participants with different levels of physical stress were included (91). Ethical approval was obtained and the patients or their legal representatives gave written informed consent to participate in the study. Group A (no stress) contained 17 healthy control subjects, mainly staff members. Group B (moderate stress) consisted of 23 patients consecutively recruited from a wide and representative variety of non-hypertensive patients having been hospitalised on the medical ward for various reasons (i.e. acute diabetic complications hyperglycaemic crisis, hypoglycemia], infections [urosepsis, exacerbation of chronic obstructive lung disease, pneumonia], inflammation [acute pancreatitis or myocarditis], hypoventilation syndrome, myocardial infarction, congestive heart failure, unstable angina pectoris, cerebrovascular insult, decompensated liver cirrhosis and ocular neuropathy). None of the patients showed clinical or laboratory features of acute or chronic adrenal insufficiency. All patients in group B had to be stable and hospitalized for at least 48 hours. Group C consisted of 24 stable surgical patients consecutively recruited from the Division of Cardiothoracic Surgery undergoing elective coronary artery by-pass grafting under general anaesthesia. These patients served as a standardized model for changing stress levels. We speculated that on the morning before operation there would be no or only minimal (if, then psychological) apparent stress, during the operation the stress would increase, while maximal stress to activate the pituitary-adrenal axis would be present after extubation, with partial resolution on the following morning. This was based on previous detailed studies of the changes in serum cortisol during and after surgery (104-107). For premedication midazolam 7.5mg was used in all surgical patients. Anaesthesia was induced with thiopentone (2-4mg/kg) and fentanyl (2-4g/kg); etomidate, which is known to cause changes in adrenal steroidogenesis, was not used (110). Intubation was facilitated with pancuronium (0.15mg/kg). Before and during cardiopulmonary by-pass anaesthesia was maintained with isoflurane (0.5 – 1.5 MAC) and fentanyl. During weaning and after bypass a continuous dormicum-fentanyl infusion was used for maintenance of anaesthesia. Routine monitoring included a continuous 2-lead electrocardiogram, pulse oximetry, end-tidal CO2 concentration, invasive arterial pressure and central venous pressure. Antibiotic prophylaxis consisted of cefuroxime (1.5g, t.i.d.) for 48h. Surgery was performed under normothermic conditions (i.e. resulting in cooling not lower than 35°C). Cardiopulmonary by-pass was started after heparin (350IU/kg) and cylocapron 30mg/kg using a hollow fiber oxyenator in all patients. Myocardial preservation during by-pass was achieved with intermittent infusion of Bretschneider's cardioplegic solution. No blood transfusion was required in any patient. The duration of the operation (incision-suture time) was on average 4 hours. The number of vessels grafted was 3.6±0.8. At the time of extubation (6 to 10hours after surgery), 57% of patients needed various amounts of catecholamines, usually adrenaline (1-10μg/min) and/or noradrenaline (1-10μg/min). Treatment with catecholamines was necessary in a decreasing manner for a total of 25±4 hours (mean±standard deviation). The median intensive care unit stay was 2 days, and no patient stayed longer than 4 days. None of the patients received corticosteroid treatment. Exclusion criteria were as follows: contraindication to receiving synthetic ACTH, i.e. allergies; patients who received drugs that influence the hypothalamo-pituitary adrenal axis during the last 3 months; patients with diseases affecting the adrenal or the pituitary gland; patients with known or suspected primary or secondary adrenal insufficiency; and patients receiving etomidate (111, 112). 

In Groups A and B, patients were tested on a single occasion between 06.00h and 09.00h. Surgical patients in Group C were evaluated at four different time points reflecting different levels of stress: C1- the morning (06.00h-09.00h) before operation; C2- during operation, 30 minutes after intubation; C3- 30 minutes after extubation; and C4- the morning after extubation (06.00h-09.00h). From previous studies (104, 105) (106, 107), it was anticipated that C3 would show maximal activation of cortisol levels.

According to the protocol (91), each participant of groups A-C was randomly assigned to be stimulated with either 1μg or 250μg ACTH by block randomisation in groups of 4, and was blinded regarding to his/her assignment. Standard ACTH stimulating tests were performed using 250g tetracosactidum (Synacthen®, Novartis Pharma, Switzerland) and 1g tetracosactidum (0.25mg tetracosactidum (Synacthen®, Novartis Pharma, Switzerland) divided into 1g tetracosactidum doses by the pharmacy of the Kantonsspital Luzern, Switzerland), as previously described (113, 114). In all subjects, blood samples were taken at time 0mins for the basal measurement of TC and FC and ACTH and again at time 30mins for measurement of serum TC and FC concentration after intravenous administration of 1μg or 250μg Synacthen® (synthetic ACTH[1-24]), respectively. 

4.12.2.	Free cortisol in patients with community-acquired pneumonia
Data from 278 patients presenting to the emergency department with community-acquired pneumonia (CAP) were analysed. 
The endpoint of this study was the assessment of prognostic factors in CAP.
Consecutive patients with CAP were included. Patients had to be >18 years with a suspected CAP as the principal diagnosis on presentation. Exclusions included patients with cystic fibrosis or active pulmonary tuberculosis, hospital-acquired pneumonia or severely immunocompromised patients. Patients were examined on presentation to the emergency department by a resident supervised by a board-certified specialist in internal medicine. Baseline assessment included clinical data and vital signs, comorbid conditions, and routine blood tests. CAP was defined by the presence of one or several of the following recently acquired respiratory signs or symptoms: cough, sputum production, dyspnoea, core body temperature >38.0° C, auscultatory findings of abnormal breath sounds and rales, leukocyte count  >10 or <4 x 109 cells L–1 and an infiltrate on chest radiograph (115). The pneumonia severity index (PSI), a validated severity scoring system for pneumonia patients, was calculated (116). The PSI has been developed to predict severity of CAP and outcome and is currently the gold standard prognostic scoring rule (116-120). It uses demographics (whether someone is older, and is male or female), the coexistence of co-morbid illnesses, findings on physical examination and vital signs, and essential laboratory findings. Chest radiographs were screened by the physician in charge and reviewed by a senior radiologist, unaware of clinical or laboratory findings. 
The study was approved by the local Ethics Committee for human studies and written informed consent was obtained from all patients. 

All patients were followed-up for a mean duration of 6.9±1.9 weeks (121). At the follow-up visit, outcome was evaluated by clinical, laboratory, radiographic and microbiological criteria. Cure was defined as resolution of clinical, laboratory and radiographic signs of CAP. Improvement was defined as reduction in clinical signs and symptoms, improvement in laboratory findings (i.e. C-reactive protein, procalcitonin and leukocyte count), and a reduction in the number or intensity of radiographic signs of CAP. Treatment success represented the sum of the rates for cure and improvement. Treatment failure included death, recurrence or persistence of clinical, laboratory and radiological signs of CAP at follow-up. Patients who survived until follow-up were counted as survivors, whereas patients who died within the follow-up period were counted as non-survivors. 

4.13.	Statistical analysis
Discrete variables are expressed as counts (percentage) and continuous variables as means ± standard error of the mean (SEM) or means ± standard deviation (SD) or median (interquartile range) unless stated otherwise. Frequency comparisons were made with the chi-square test. Two-group comparison of normally distributed data was performed by Student’s t-test. For multigroup comparisons, one-way analysis of variance with least square difference for post hoc comparisons was applied. For data not normally distributed, the Mann-Whitney-U test was used if only two groups were compared and the Kruskal-Wallis one-way analysis of variance was used if more than two groups were being compared. For cell experiments with metformin and dexamethasone alone and combined treatment with dexamethasone + metformin two-way ANOVA was used. Receiver-operating-characteristics were calculated by STATA (version 9, Statacorp, Texas, USA). Correlation analyses were performed by using Spearman rank correlation. 
All testing was two-tailed and P values less than 0.05 were considered to indicate statistical significance, *P<0.05, **P<0.01 and ***P<0.001. 


5	RESULTS
Project A: Effect of corticosteroids on AMPK
5.1.	Hormonal parameters of in vivo rat experiment
In glucocorticoid treated rats plasma corticosterone levels were higher, and accordingly, plasma ACTH levels were lower, as compared to the two control groups (P=0.001 and 0.007, for the sucrose and saline controls respectively) (Figure 6a and b). 
Plasma insulin concentrations were higher in corticosterone-treated rats as compared to the two other groups (P=0.002) with compensated glucose concentrations (Figure 6c and d). The calculated HOMA index revealed a value of 2.2±0.3 for corticosteroid-treated rats, suggesting insulin resistance, whereas the index was normal in the two control groups (0.9±0.07 and 0.8±0.1). 
Plasma leptin levels were higher in the corticosterone treated rats as compared to the two other groups (P=0.005) (Figure 6e). In contrast, no difference was seen in either adiponectin or ghrelin levels between the three groups (Figure 6f and 6g). 
Corticosteroid treated animals had significantly higher plasma total cholesterol levels as compared to the two control groups (P=0.003) (Figure 6h). By contrast, triglyceride levels were higher in sucrose-drinking animals treated with either cholesterol or corticosterone (Figure 6i). The more pronounced effect of corticosterone per se on hypercholesterolaemia compared to hypertriglyceridaemia is concordant with data reported in Cushing’s syndrome in humans (122). 


Figure 6: Hormone levels; biochemical and hormonal parameters in plasma in corticosterone (Cort, n=8) treated rats as compared to rats with cholesterol pellets drinking sucrose (Sucr, n=6) or saline (NaCl, n=6). 
6a Corticosterone:			 			6b ACTH
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6h Total cholesterol						6i Triglycerides


5.2.	Energy balance and metabolic effects 

Sucrose intake was higher in the corticosterone treated rats compared to the sucrose drinking controls. In contrast, chow intake was highest in the saline drinking rats (P<0.001). As expected, total calorie intake was higher in the two sucrose drinking groups as compared to saline drinking animals (P<0.001), and there was a trend for higher calorie intake in corticosterone-treated animals drinking sucrose compared to sucrose alone (P=0.07) (Figure 7a-c). 
Based on these findings, I calculated the caloric efficiency (grams gained/calorie ingested): appropriate to the marked catabolism of corticosteroid treated animals, caloric efficiency was lowest in the corticosterone-treated animals, and was also lower in sucrose-drinking control rats compared to saline-drinking rats (P<0.001) (Figure 7d). Therefore, corticosterone-treated rats gained significantly less weight compared to the two other groups (P=0.004) (Figure 7e). 

Figure 7: Weight gain and metabolic effects within 14 days in corticosterone (Cort, n=8) treated as compared to rats with cholesterol pellets implanted either drinking sucrose (Sucr, n=6) or saline (NaCl, n=6). Caloric intake includes both, chow and sucrose calories ingested. Caloric efficiency was calculated as body weight gained/kcal ingested. 

Fig. 7a Sucrose intake	 				7b Chow intake
					




Fig. 7c Total calorie intake 				7d Caloric efficiency




7e Weight gain




5.3.	Metabolic changes in adipose tissue

5.3.1. Animal study: 
Visceral white adipose fat depot was higher in corticosterone-treated rats (P=0.01) as compared to the other two groups whereas the inguinal fat depot, a measure of subcutaneous fat, was similar between corticosteroroid treated rats and sucrose drinking control rats (P=0.3) (Figure 8a and b). 

Figure 8: Weight of adipose tissue depots 
Fig. 8a Visceral fat pad weight			8b Inguinal fat pad weight





The influence of corticosterone treatment on AMPK activity was investigated in adipose tissue. In visceral fat AMPK activity was significantly lower as compared to the two control groups (P=0.008). In contrast, in subcutaneous fat there was no difference in AMPK activity between the three groups (P=0.16) (Figure 9a-b). 

Figure 9: Effect of corticosteroids versus placebo on adipose tissue AMPK activity
Fig. 9a AMPK activity in visceral fat		9b AMPK activity in subcutaneous fat





Real-time RT-PCR was performed in rat tissue. In the visceral adipose tissue of rats, PEPCK and HSL mRNA were significantly higher in corticosteroid-treated animals as compared to the two other groups (P=0.01 and 0.006), and FAS and SREBP mRNA were higher in corticosteroid-treated rats compared to saline drinking rats (P=0.03 and 0.02). In contrast, no difference between these gene products was seen in subcutaneous rat adipose tissue except for a significantly higher HSL mRNA in subcutaneous adipose tissue of corticosteroid treated rats (Figure 9c), suggesting an influence of corticosteroids on gluconeogenesis and lipogenesis mainly in visceral fat tissue. 



Fig. 9c Real-time RT-PCR (FAS, PEPCK, SREBP and HSL) in visceral (upper panel) and subcutaneous (lower panel) rat adipose tissue










The predominant AMPK subunit in adipose tissue, AMPK 1, showed no difference in mRNA expression between the groups (Figure 9d), while the expression level of the 2 subunit was minimal.

Fig. 9d Real-time PCR for AMPK α subunit 1



5.3.2. In vitro study: 
AMPK activity in human adipocytes treated with dexamethasone 10-6M for 24 hours was lower as compared to saline treated adipocytes (P=0.04) (Figure 9e). . 
The dose-response curve with metformin 0.1 to 10mM showed that metformin at doses of 1mM and 10mM significantly induced AMPK activity in human adipocytes compared to the control (P=0.005). The inhibitory effect of dexamethasone on AMPK activity was antagonised by co-administration of metformin 10mM, which increased AMPK activity to 224±14% compared to dexamethasone treatment alone (P=0.003, Figure 9e).

Fig. 9e AMPK activity in human adipocyte cell culture in vitro in response to dexamethasone and metformin, n=3. P overall (two-way ANOVA) <0.001


As a downstream enzyme of AMPK we studied FAS in response to metformin and dexamethasone: Dexamethasone 1μM for 24h significantly stimulated expression of the downstream enzyme (174±30% of control, P<0.05, Figure 9g). Metformin (10mM) treatment on its own inhibited FAS expression (63±11%) and this inhibition was abolished by dexamethasone (metformin vs. dexamethasone+metformin, P<0.001). 

Fig. 9g FAS mRNA in human adipocyte cell culture in response to dexamethasone and metformin, n=3







The effect of dexamethasone on glucose uptake in human adipocytes was also studied (Figure 9h). Basal glucose uptake was inhibited by dexamethasone (77±1% of control, P<0.05) and stimulated by metformin (231±10% of control, P<0.001), while co-administration of dexamethasone+metformin decreased basal glucose uptake compared to metformin alone (P<0.05). Similar results were obtained when insulin-induced glucose uptake was studied: dexamethasone inhibited (89±0.7% of insulin alone, P<0.05), while metformin further stimulated, insulin-induced glucose uptake (176±2% of insulin alone, P<0.001). Co-administration of dexamethasone+metformin decreased insulin-stimulated glucose uptake as compared to metformin alone (P<0.05).  
Insulin induced glucose uptake by 2.3 fold. 




Fig. 9h Glucose uptake in human adipocytes, n=1








5.3.3. Human study: 
Baseline characteristics of the included patients are shown in Table 2. 

Table 2: Clinical characteristics of the patients
	Adrenal incidentalomas (n=9)	Cushing’s syndrome (n=11)	P-value
Age (yr)	53 ± 8	50 ± 11	NS
Sex (m/f)	5/4	2/9	NS
BMI (kg/m2)	30 ± 3	32 ± 7	NS
09.00 h cortisol (μg/dl) [nmol/L]	13.8 ± 4.5 [381 ± 124]	26.8 ± 7.8 [745 ± 221]	<0.001
Urinary free cortisol (μg/24h) [nmol/24h]	96.4 ± 29.3 [265 ± 81]	447 ± 564 [1233 ± 1559]	<0.0001
Cortisol after Dexa 1mg (μg/dl) [nmol/l]	2.01 ± 1.04 [58 ± 29]	20.5 ± 13.8 [579 ± 386]	<0.001
ACTH (pg/ml) [pmol/L]	26.5 ± 12.5 [5.8 ± 2.8]	6 ± 2.2 [1.3 ± 0.4]#	0.002

All data are shown as mean ± standard deviation. NS, not significant; Dexa 1mg, overnight dexamethasone test with 1mg oral dexamethasone. Normal range for 9 a.m. serum cortisol: 5-23μ/dl [138-635 nmol/l], for urinary free cortisol: 13-160μg/24h [35.9-441.4 nmol/24h], cortisol after overnight dexamethasone test: 1.8 μg/dl and ACTH 7-65pg/ml [1.54-14.3 pmol/L]. # The single patient with pituitary-dependent Cushing’s disease with circulating ACTH of 8.6pmol/l was not included in the ACTH calculation in the table above. 


There was a significant difference between patients with Cushing’s syndrome and adrenal incidentalomas in 09.00h serum cortisol (mean ± standard deviation, 26.8 ± 7.8 vs. 13.8 ± 4.5μg/dl, P<0.001 [742 ± 216 vs. 381 ± 124nmol/L]), urinary free cortisol (447 ± 564 vs. 96.4 ± 29.3μg/24h, P<0.0001 [1229 ± 1553 vs. 265.2 ± 81nmol/24h]), 09.00h serum cortisol levels after 1mg dexamethasone at midnight (20.5 ± 13.8 vs. 2.01 ± 1.04μg/dl, P<0.001 [568 ± 383 vs. 57.9 ± 28.8nmol/L]), and plasma ACTH (6 ± 2.2 vs. 26.5 ± 12.5ng/L, P=0.002 [1.3 ± 0.4 vs. 5.8 ± 2.8pmol/L]) (Table 2). Some of the patients with adrenal incidentalomas, in accordance with clinical data, had a slight increase in their cortisol burden (subclinical Cushing’s syndrome), as demonstrated by the fact that 3 out of 9 patients failed to fully suppress their 09.00h serum cortisol to <1.8g/dl (<50nmol/L). The two groups were not significantly different in terms of age, sex or body mass index (BMI). 
The 4 patients with non-endocrine-related perirenal operations were all male. They had a mean age of 33 ± 12 years and had a mean BMI of 24 ± 3. 

AMPK activity in visceral adipose tissue: 
I observed a more than 70% reduction in AMPK activity in the tissue samples from patients with Cushing’s syndrome compared to either of the other patient groups. AMPK activity was significantly decreased in the visceral adipose tissue samples from patients with Cushing’s syndrome compared to patients with adrenal incidentalomas (0.08 ± 0.03 vs. 0.3 ± 0.07nmol/min/mg, P=0.007, Figure 10). Since patients with incidentalomas have been shown to occasionally present with signs of mild hypercortisolism, I also evaluated AMPK activity in the perirenal adipose tissue from patients with perirenal operations without underlying endocrine disease. The AMPK activity in patients with Cushing’s syndrome was again significantly lower compared to these control patients (AMPK activity 0.08 ± 0.03 vs. 0.54±0.1nmol/min/mg, P<0.001, Figure 10). The comparison between AMPK activity of fat tissue from incidentaloma patients and non-endocrine disease patients showed a non-significant trend (P=0.11) for lower levels in the incidentaloma patients (Figure 10). 

Figure 10 Effect of corticosteroids on AMPK activity in human visceral adipose tissue 








In patients with Cushing’s syndrome and adrenal incidentalomas, AMPK activity correlated negatively with 09.00h serum cortisol (r=-0.51, P=0.02); this was also true in the patients with Cushing’s syndrome alone (r=-0.67, P=0.03, Figure 11). Urinary free cortisol also correlated negatively with AMPK activity (r=-0.53, P=0.027) in patients with Cushing’s syndrome and adrenal incidentalomas, while cortisol levels after 1mg dexamethasone test showed a non-significant trend for negative correlation (r=-0.48, P=0.054). Plasma ACTH levels, on the other hand, correlated positively with AMPK activity (r=0.51, P=0.04; the patient with Cushing’s syndrome due to pituitary adenoma was excluded from this last analysis).


Figure 11 correlation of AMPK activity with 09.00h serum cortisol levels







FAS and PEPCK are important rate-limiting enzymes in fatty acid synthesis. Real-time RT-PCR revealed up-regulation of FAS mRNA in visceral adipose tissue in patients with Cushing’s syndrome as compared to the control patients (240 ± 104.3% of control, P=0.01, Figure 12), while values for incidentaloma patients were in between controls and Cushing’s patients (178.5±29.9% of control) (P=0.12 vs. Controls, P=0.13 vs. Cushing’s). PEPCK mRNA expression showed a non-significant trend to be higher in patients with Cushing’s syndrome vs. control subjects (228.79 ± 50.5% of control, P=0.19).

Figure 12 Real-time PCR (FAS and PEPCK) in human fat tissue







5.4.	Metabolic changes in the liver

To confirm the metabolic effects of corticosteroids on the liver, lipid staining of the rat livers was performed. Corticosterone-treated rats showed a higher liver lipid content as compared to cholesterol-treated rats drinking either sucrose or saline (P=0.002) (Figure 13a), concordant with the fatty liver described in patients with Cushing’s syndrome (62). Accordingly, real-time RT-PCR showed a higher expression of FAS mRNA in corticosteroid-treated rats as compared to the two control groups (P<0.001). Expression of PEPCK, SREBP1c and G6P was not different in glucocorticoid-treated rats compared to the control rats (Figure 13b). AMPK activity in the liver was significantly higher in corticosterone-treated rats as compared to the two other groups (P=0.01) (Figure 13c). 
To investigate whether the observed effect was direct or indirect,  a human hepatoma cell line was used. Here, I noted significant stimulation of AMPK activity following dexamethasone 10-6M treatment on AMPK activity after 6h as compared to control cell cultures (P<0.001) (Figure 13d). 
Real-time RT-PCR for AMPK 1 showed that the expression was higher in the saline drinking rats as compared to the corticosteroid-treated animals (P=0.01) (Figure 13e). There was no difference in AMPK 2 subunit expression between the three groups. 



Figure 13 Effect of corticosteroids versus Placebo on liver AMPK activity
Fig. 13a Lipid staining: Liver sections were stained with Oil-Red-O and with Mayer’s haematoxylin. Staining of sections was scored for a) droplet distribution (universal, zonal, negative) and b) for staining intensity in positive cells (strong, weak). The analysis was done by adding the score of a) and b) together.











Fig. 13b Real-time RT-PCR results liver








Fig. 13c AMPK activity in liver 		13d AMPK activity in Hep G2 cells, n=3 






Fig. 13e Real-time PCR for AMPK subunits 1 (left panel) and 2 (right panel)






5.5.	Metabolic changes in the hypothalamus

Patients with Cushing’s syndrome demonstrate increased appetite (60), and I therefore studied the influence of corticosteroids on AMPK activity in the hypothalamus. I observed a higher AMPK activity in corticosterone-treated rats as compared to sucrose-drinking control rats (P<0.001). The lower AMPK activity in sucrose-drinking control rats compared to saline drinking control rats confirms the inhibitory effect of sucrose on hypothalamic AMPK activity (40, 41). Corticosterone administration counteracted the effects of sucrose and increased hypothalamic AMPK activity to levels comparable to saline drinking animals (Figure 14a). 
These findings are compatible with an increase in appetite, and  a trend (P=0.07) was also observed for an increase in total calorie intake in corticosterone treated rats compared to sucrose drinking rats. 

Figure 14 Effect of corticosteroids versus Placebo on hypothalamic AMPK activity 
Fig. 14a AMPK activity hypothalamus		






To explore possible mechanisms as to how corticosteroids increase hypothalamic AMPK activity, the endocannabinoid content in the three groups of animals was measured. Similar to the pattern of the AMPK activity, the endocannabinoid 2-AG content was higher in corticosterone-treated rats than in sucrose-drinking control rats (P=0.03). The endocannabinoid content of anandamide was not different (Figure 14b). 
Fig. 14b Endocannabinoid (2-AG, AEA) content






Primary rat hypothalamic cell cultures showed a non-significant increase of the AMPK activity after treatment with dexamethasone 1μM for 6h (P=0.68), Figure 14c). Metformin alone decreased AMPK activity, however, not significantly (P=0.21). Addition of 10mM metformin inhibited the effect of dexamethasone and decreased AMPK activity to 26±2% of the level seen with dexamethasone alone (P=0.006), Figure 14c). 

Fig. 14c AMPK activity in primary hypothalamic cultures in response to dexamethasone and metformin, n=3. P overall (two-way ANOVA) = 0.01

5.6.	Metabolic changes in the skeletal and heart muscle

In skeletal muscle, I found no difference in AMPK activity in either white or dark muscle between the three groups (Figure 15a). In the heart, AMPK activity was lower in corticosterone-treated rats as compared to the other two groups (P<0.001) (Figure 15b). 




Figure 15 Effect of corticosteroids versus placebo on skeletal and heart muscle AMPK activity
Fig. 15a AMPK activity in white skeletal muscle 	Fig. 15b in dark skeletal muscle 






Fig. 15c AMPK activity in heart muscle









Project B: Free and total cortisol in critical illness
5.7.	Study 1: Comparison of free and total cortisol in patients with increasing levels of stress 
Baseline characteristics of the study population are shown in table 3. 

Table 3: Characteristics of the study group (Group A-C)
	Healthy controls(Group A, n=17)	Medical patients(Group B, n=23)	Surgical patients undergoing CABG (Group C, n=24)	P
			Preoperative	Day 1 postop.	
Age (yr)	47 ± 15	66 ± 13	64 ± 9	<0.001
Sex (m/f)	8/9	14/9	24/0	<0.001
BMI (kg/m2)	23 ±3	30 ± 6	24 ± 3	0.001
1μg/250μg	7/10	11/12	12/12	NS
Hospitalization (d)		21 ± 14	12 ± 6	0.002
Mean blood pressure (mmHg)		90 ± 12	90 ± 11	89 ±  11	NS


Basal and stimulated total and free cortisol concentrations in different stress levels
Basal TC levels in controls were 496.1±132 nmol/l and in the medical patients 468.5±143 nmol/l; in the surgical patients on the morning before operation they were 382.0±159 nmol/l, during the operation 532.7±400 nmol/l, after extubation 811.4±268 nmol/l, and the day after operation 604.4±288 nmol/l (P<0.001). The respective FC levels were 36.9±17.2 nmol/l, 43.5±18.9, 34.8±16.9, 31.3±26.4, 107.8±55.8 and 63.6±39.3 (P<0.001 for analysis of variance) (Figures 16a and b). The respective post-ACTH total and free cortisol levels are shown in Figures 16a and b. 

Figure 16 Total (a) and free (b) cortisol levels in controls, medical patients and surgical patients at the 4 different time points (C1, before the operation; C2, during the operation; C3, after extubation; C4, one day after the operation). Diamonds denote means, squares SEM and whiskers 1.96 SEM of the combined data.

Fig. 16a							16b 








Figure 17 Total (a) and free (b) cortisol levels after ACTH stimulation in controls, medical patients and surgical patients at the 4 different time points (C1, before the operation; C2, during the operation; C3, after extubation; C4, one day after the operation). Diamonds denote means, squares SEM and whiskers 1.96 SEM of the combined data.
Fig. 17a							17b

Post hoc analyses revealed significantly higher TC and FC levels after extubation as compared to all other groups. There was no significant difference for TC levels between the control group, medical patients and surgical patients at baseline, before operation or the day after operation. 

Basal total and free cortisol concentrations upon major stress
FC levels increased after extubation (i.e. major stress) to 399.1±266 % of initial values (P<0.001 compared to baseline) while TC levels increased to 247.1±132 % of initial values (P<0.001 compared to baseline). The percentage increase in FC levels was significantly more pronounced as compared to the increase in TC levels (P=0.02). The FC index (TC/CBG) increased to 335.5±181.2%. FC levels decreased the day after extubation to 66.7±49% of levels after extubation (P=0.003). TC levels decreased to 79.4±36% of levels after extubation (P=0.01). The decrease in FC levels was significantly more pronounced as compared to TC levels (P=0.04). The FC index decreased to 78.7±34%. In surgical patients with major stress, FC levels correlated significantly with the calculated FC index (r2=0.59, P<0.001). 

Comparison between the increase in basal cortisol levels in major stress and the increase upon stimulation with ACTH in a non-stressed situation
In surgical patients at baseline, the increase in basal FC and TC levels with either 1μg or 250µg ACTH was not significantly different, and we therefore pooled the data. After ACTH stimulation, TC levels increased to 679.9±168nmol/l, which was not significantly different to that seen after major stress (811.4±268, P=NS). FC levels increased to 107.8±56 nmol/l with major stress after extubation, markedly and significantly higher than after ACTH stimulation (55.1±16nmol/l, P<0.001) (Figure 18a and b). 

Figure 18 Total (a) and free (b) cortisol levels in surgical patients without stress (before operation) after ACTH testing (left side) as compared to levels upon major stress (after extubation, right side). The median level is shown with dot plots representing the absolute values.

Fig. 18a						 18b







Percentage of free cortisol to total cortisol in different stress conditions
Under basal conditions in surgical (group C) patients, the percentage of basal FC to basal TC was 9.1±3.0%. With major surgical stress after extubation, this percentage of FC to TC increased to 13.1±3.9% (P<0.001). 

Albumin and CBG with major stress in surgical patients
Albumin levels in surgical patients before operation were 41.0±3.6g/l, during operation 21.7±3.4g/l, after extubation 23.8±2.6g/l, and the day after extubation 23.4±2.3g/l (P<0.001). Serum CBG levels at the respective time points were 27.7±7.5g/l, 26.1±7.9, 19.3±3.9 and 19.8±4.9 g/l (P<0.001). Post hoc analysis revealed a significant decrease in albumin, but not in CBG, during the operation (for comparison between C1 and C, P<0.001 and 0.34, respectively). For CBG, post hoc analysis revealed a significant decrease after extubation (for comparison between C2 and C3, P<0.001), whereas there was no significant decrease in albumin levels (P for comparison between C2 and C3=NS) (Figure 19a and b). 

Figure 19 Albumin (a) and CBG (b) levels in the surgical patients at the 4 different time points (C1, before the operation; C2, during the operation; C3, after extubation; C4, one day after the operation). Diamonds denote means, squares SEM and whiskers 1.96 SEM of the combined data.

Fig. 19a							19b



Figure 1

Difference between 1- and 250μg stimulation test
In the control group and in medical patients and surgical patients before operation, the percentage increases in FC or TC levels were similar after 1g or 250g ACTH respectively. In surgical patients after extubation, TC levels increased to 931.7±231nmol/l after 1g (P=0.03) and to 1186.1±327 after 250g ACTH (P=0.01). FC levels increased to 123.3±42nmol/l after 1g ACTH (P=0.04) and to 163.8±51 after 250g (P=0.01). The increase with 250g ACTH was more pronounced as compared to the increase with 1g ACTH for FC (P=0.01), but not for TC. 

Correlation of total and free cortisol levels with parameters of inflammation / infection
C-reactive protein and procalcitonin levels as parameters of inflammation and infection (123) showed a significant increase with surgery (P<0.01 comparing before surgery [C1] to after extubation or the day after extubation [C3 and C4]). There was a significant correlation of TC and FC with C-reactive protein and procalcitonin levels (r=0.45 and 0.39 for TC, and r=0.55 and 0.60 for FC). 

5.8.	Study 2: Comparison of free and total cortisol to predict outcome in patients with community-acquired pneumonia 

Patients 
Detailed baseline characteristics of the study population are summarized in Table 4. 







Table 4 Baseline Characteristics of the 278 Patients*
Characteristic
Age - years 	69  17
Male sex - no. (%)	174 (63)
Smoking statusCurrent smoker – no. (%)Packyears history in smokers	71 (26)41.6  25.5
Antibiotic pretreatment (%)	56 (20)
Coexisting illnesses - no. (%)Coronary artery diseaseHypertensive heart diseaseCongestive heart failurePeripheral vascular diseaseCerebrovascular diseaseRenal dysfunctionLiver diseaseDiabetes mellitusChronic obstructive pulmonary diseaseNeoplastic disease	88 (32)72 (26)15 (5)19 (7)16 (6)74 (27)30 (11)57 (21)66 (24)43 (16)
History- no. (%)CoughSputumDyspnea	247 (89)201 (72)209 (75)
Examination - no. (%)Rales	249 (90)
Laboratory findings C-reactive protein (mg/l) (median-IQ range)Procalcitonin (μg/l) (median-IQ range)Leukocyte count (x109)Total cortisol (pmol/l) (median-IQ range)Free cortisol (pmol/l) (median-IQ range)	132 (67-212)0.5 (0.2-2.3)12.7 (9.1-16.3)716 (423-1209)52.8 (34.5-90.5)
Radiographic findings– no. (%)Pleural effusionMultilobar CAP	36 (13)48 (17)
	
PSI - pointsPSI class – no. (%)I, II and IIIIVV	99.1  35.5111 (40)120 (43)47 (17)
       *Plus-minus values are means  SD. Because of rounding, percentages may not sum to 100
The mean age of the 278 patients was 69±17 years; 71 (25.5 percent) were smokers and 56 (20.1 percent) had been pretreated with antibiotics. Overall, 87 percent of patients had relevant co-morbidities. No patient was on etomidate, barbiturates or muscle relaxants: 21 patients (7.6%) were taking sedative drugs which may interact centrally with the pituitary-adrenal axis (124). Total and free cortisol levels in patients with and without these drugs were not significantly different. 
The mean PSI of all patients was 99.1 ± 35.5 points: 22 patients (7.9 percent) had a PSI class I, 37 (13.3 percent) a PSI class II, 52 (18.7 percent) a PSI class III, 120 (43 percent) a PSI class IV and 47 (17 percent) a PSI class V. No patient on presentation was on intravenous steroid treatment; 27 patients had oral corticosteroid intake on presentation (corresponding to a median dose of 5 mg prednisone daily, range 2.5-50 mg daily). Therefore, all analyses were performed including and excluding these patients, respectively. 

Total and free cortisol levels and severity of CAP
Both total and free cortisol levels increased with increasing severity of CAP, classified according to the PSI score (P<0.001) (Figure 20). Mortality in patients with PSI I-III was 1.8%, 16% in patients with PSI IV and 21% in patients with PSI V (Figure 20).


Figure 20 Total and free cortisol levels in different severities of community-acquired pneumonia. Data are shown as means ± SEM with scatterplots representing all values. PSI denotes pneumonia severity index. The first line of mortality rates indicates the mortality rate given by the original publication (116). The second line indicates the mortality rates as assessed in our study cohort.












Post hoc analysis revealed a significant difference in free cortisol levels (P=0.04) but not in total cortisol levels (P=0.23) between PSI groups IV and V. The gradual increase with PSI class was also significant for procalcitonin (P<0.001), but not for C-reactive protein (P=0.24) or for total leukocyte count (P=0.13). Serum albumin levels showed a trend towards lower levels with higher PSI class (P=0.06). The results remained similar when excluding patients with corticosteroid therapy on presentation. 
Four patients (1.4%) were hypotensive with a systolic blood pressure <90mmHg at presentation to the ED. The total and free cortisol levels in these patients were 1304.5 (834-1805) nmol/l and 160.1 (85.3-279.8) nmol/l respectively. As we report data on presentation to the ED, the consensus criteria to define septic shock which include adequate fluid resuscitation over several hours (125, 126) do not apply and no patient was formally classified as having septic shock. 
There was a significant correlation between total and free cortisol levels (r = +0.71, P<0.001). The correlation was still significant when taking into account only patients with hypoalbuminaemia (i.e. albumin <2.5g/l (88)) (r=+0.68, P<0.001). Total and free cortisol levels correlated with other markers of infection, i.e. procalcitonin (r = +0.30 and +0.37, P<0.001 for both), C-reactive protein (r = +0.20 and +0.27, P<0.001 for both), and total leukocyte count (r = +0.14 and r = +0.17, P<0.05 and P<0.01, respectively). 

Total and free cortisol levels as prognostic marker for outcome
At follow-up, 245 patients survived and 31 patients died. Two patients were lost to follow-up. Thus, the overall mortality rate was 11.2 percent. The mortality in the patients on corticosteroids was 3 of 27 patients (11.1%). 

For the subsequent analyses, only steroid-naïve patients were considered. On presentation, total and free cortisol levels in patients who died during follow-up were significantly higher as compared to levels in survivors (1141 (941-3355) and 88.4 (51.9-124.1) vs. 697 (429-1081) and 52.4 (35.0-88.9) nmol/l; P<0.001 and 0.001, respectively, Figure 21). 



Figure 21 Total and free cortisol levels in survivors and non-survivors. 
Data are shown as means ± SEM.


Albumin levels tended to be lower in non-survivors (27.7 ± 6.8) compared to survivors (30.8±6.2; P=0.07).  The respective values were not significant for procalcitonin (0.6 (0.4-2.2) vs 0.5 (0.2-2.4), P=0.08, for C-reactive protein 145 (101-204) vs. 132 (66-212) mg/l, P=0.64 or for total leukocyte count 13.5 (11.4-16.5) vs 12.1 (9.0-15.6), P=0.18). 

To evaluate the potential to predict death in CAP, a receiver operating characteristic (ROC) analysis was performed where sensitivity was calculated with those patients who died until follow-up (n=28) and specificity was assessed with those patients who survived until follow-up (n=223). The area under the ROC curve (AUC) and likelihood ratios for different cut-off points are summarized in Table 5. 



Table 5a: Prediction of mortality (death) in patients with Community-acquired pneumonia  (n=251)
Area under the curve of receiver operating curve characteristic plot analysis
Parameter	AUC	95% CI	P (vs TC)	P (vs FC)
Total cortisol (TC)	0.76	0.70-0.81	-	0.12
Free cortisol (FC)	0.69	0.63-0.74	0.12	-
C-reactive protein	0.53	0.47-0.59	0.001	0.01
Leukocytes	0.58	0.51-0.63	0.01	0.16
Procalcitonin	0.60	0.54-0.66	0.02	0.17
Pneumonia severity index	0.76	0.70-0.81	0.96	0.25
AUC, Area Under the Curve; SD, Standard Deviation, CI, Confidence Interval

Table 5b: Total and free cortisol and PSI thresholds to predict mortality
Sensitivity, Specificity, positive likelihood ratio, negative likelihood ratio at different cut off levels
Cut off TC	Sensitivity 	Specificity 	LR+	LR-
594	89.3	42.6	1.56	0.25
960	75.0	71.7	2.65	0.35
1650	42.9	88.8	3.82	0.64
Cut off FC	Sensitivity 	Specificity 	LR+	LR-
48.8	85.7	47.7	1.64	0.30
80.3	64.3	71.6	2.27	0.50
106.8	42.9	85.1	2.88	0.67
Cut off PSI	Sensitivity 	Specificity	LR+	LR-
90	96.4	46.2	1.79	0.08
101	89.3	59.2	2.19	0.18
134	32.1	87.4	2.56	0.78
TC, total cortisol; FC, free cortisol; LR +, Positive Likelihood Ratio, LR -, Negative Likelihood Ratio

The prognostic accuracy of total, more than free, cortisol to predict death was superior to CRP and leukocyte count and procalcitonin, and was comparable to the PSI score (Figure 22). 
Figure 22: Receiver operator curve analysis of different laboratory parameters predicting survival in community-acquired pneumonia. Data on presentation are shown.

Figure 18








With an optimal calculated total cortisol threshold of 960 nmol/l sensitivity and specificity were 75.0% and 71.7% with a positive and negative likelihood ratio of 2.65 and 0.35, respectively. For free cortisol with an optimal threshold of 80.3 nmol/l sensitivity was 64.3% and specificity 71.6% with a positive and negative likelihood ratio of 2.27 and 0.50, respectively. The results for the different parameters to predict treatment failure were similar (data not shown). 
To estimate the additive value of total cortisol on the PSI score we calculated a logistic regression model combining the PSI score and the total cortisol concentration. With an AUC of 0.79 (95%CI 0.71-0.87) the combined model tended to improve the prognostic accuracy of the PSI alone (p=0.22). 

When we performed a comparison of survival in patients with total and free cortisol levels below and above these calculated optimal cut-off values by Kaplan-Meier survival curves, patients with total or free cortisol levels above this cut-off had significantly lower survival rates compared to patients with levels below the cut-off (P<0.0001 and P<0.001 respectively, Figure 23). 


Figure 23 Kaplan-Meier curves. 
These show survival rates stratified by calculated, optimal total (> 960nmol/l) and free cortisol (>80nmol/l) levels, respectively. P=log rank test























When entering total and free cortisol, procalcitonin, C-reactive protein, leukocytes and the PSI in a univariate regression analysis, only increasing total (P<0.001) and free cortisol levels (P=0.004) and a rise in PSI (P<0.001) were predictors of death (Table 5). In a multivariate analysis, the predictive power of total cortisol equalled the prognostic power of the PSI (Table 6). The results for the different parameters to predict treatment failure were similar (data not shown).

Table 6: Prediction of mortality in univariate and multivariate regression analysis (n=251)
Univariate analysis
Predictor	Odds ratio (95% CI)	P-value
Total cortisol 	1.001 (1.000 – 1.001)	<0.001
Free cortisol	1.011 (1.004 – 1.018)	0.004
C-reactive protein	0.999 (0.995 – 1.003)	0.92
Leukocytes	1.033 (0.981 – 1.088)	0.21
Procalcitonin	0.998 (0.969 – 1.027)	0.87
Pneumonia severity index	1.024 (1.012-1.036)	<0.001

Multivariant biomarker analysis
Predictor	Odds ratio (95% CI)	P-value
Total cortisol	1.001 (1.000 – 1.001)	0.002
Free cortisol 	0.997 (0.987-1.007)	0.56
Pneumonia severity index	1.017 (1.004 – 1.001)	0.01

In addition, I also calculated whether particularly low, as well as high cortisol levels, as defined by Cooper et al. (127) and Annane et al. (128), were associated with poor outcome. Overall, 54 patients (19%) had total cortisol levels below 414 nmol/l while 30 patients (11%) had total cortisol levels below 275nmol/l. Of the 30 patients with total cortisol levels below 275nmol/l, 2 died (6.7%), while of the 54 patients with a total cortisol level below 414nmol/l, 3 patients died (5.6%), whereas overall mortality was 11.2%. This difference between mortality in patients with low cortisol levels and overall mortality was not statistically significant.
6.	DISCUSSION

Project A

Corticoid excess leading to Cushing’s syndrome may be caused by endogenous hypercortisolism or, more frequently, due to exogenous glucocorticoid administration for a wide range of diseases. In this study, I have hypothesised that many of the most detrimental metabolic effects, especially those related to the metabolic syndrome, might be mediated by glucocorticoid-induced changes in AMPK activity, and the results broadly support this possibility. The results show that corticosterone changes AMPK activity in various tissues in a manner that may explain the increase in food intake, lipid deposition in visceral adipose tissue, fatty liver and some of the classical peripheral cardiac effects of Cushing’s syndrome. 
The rats treated with corticosterone pellets had significantly increased corticosterone and decreased ACTH levels, became markedly hyperinsulinaemic and hyperleptinaemic, and showed high triglyceride and cholesterol values and developed visceral obesity therefore providing a model of glucocorticoid excess. Thus, the amount of corticosterone released from the pellet provides appropriate glucocorticoid excess to mimic the metabolic consequences of iatrogenic or endogenous Cushing’s syndrome (94). However, in rats, it is well known that chronic stressors associated with corticosterone excess usually decrease chow intake (94), leading to marked catabolism and weight loss. This is in contrast to humans, who generally demonstrate weight gain and increased appetite in response to excess glucocorticoids. However, sucrose drinking corticosteroid treated rats show many symptoms of the Cushing’s syndrome and are considered as the best animal model to study chronic excess glucocorticoid action and the consequent insulin resistance (95). 

Typically, with excess glucocorticoid activity there is a detrimental shift from the more inert subcutaneous fat to accumulation of the metabolically more disadvantageous visceral, intra-abdominal fat (61). Glucocorticoids regulate the differentiation of adipose stromal cells and affect the function of adipocytes leading to the accumulation of lipid. These effects are more pronounced in visceral than in subcutaneous fat, suggesting that glucocorticoids may play a pivotal role in the pathogenesis of central obesity (129). I was also able to show several changes which were present in visceral but not in the subcutaneous fat in the corticosterone-treated animals. AMPK activation in adipose tissue inhibits lipogenesis and lipolysis, and stimulates lipid oxidation. Thus, inhibition of AMPK leads to increased lipid stores in association with enhanced lipolysis, leading to the release of free fatty acids (10). AMPK activity in my experiment was significantly decreased in visceral (but not in subcutaneous) adipose tissue, as compared to controls. Therefore, I suggest that this is at least one of the mechanisms for the prominent effect of corticosteroids in accelerating lipid deposition in visceral adipose tissue. In agreement with the lower AMPK activity, the gene expression of FAS, SREBP, PEPCK and HSL was increased in corticosteroid-treated animals. 
We also showed that excess glucocorticoids are associated with a fall in adipose tissue AMPK activity in human visceral adipose tissue. We used adrenal incidentalomas as a control group for patients undergoing laparoscopic adrenalectomy, but also included a second group of patients without any adrenal pathology. Patients with adrenal incidentalomas may show subtle minor defects in corticosteroid secretion and regulation, sometimes resulting in sub-clinical Cushing’s syndrome (130-132) and indeed the fall in lipid AMPK was intermediate in these patients compared to those without any adrenal pathology. The findings of a decreased AMPK activity in the visceral adipose tissue of patients with Cushing’s syndrome with a consequent increase in the expression of the lipid synthesising enzyme fatty acid synthase could readily explain the accelerated lipid deposition in visceral adipose tissue upon glucocorticoid excess. The data also suggest that the suppression of AMPK activity is proportional to the glucocorticoid burden. 
I was able to show that incubation of human adipocytes with dexamethasone led to a fall in AMPK activity. 
Although 1 subunit is the predominant subtype in adipose tissue, there was no change in its mRNA expression with glucocorticoid treatment. Thus, based on these data one could speculate that the phosphorylation of AMPK, but not the total level of AMPK, is inhibited by treatment with glucocorticoids. 

Apart from fat tissue, glucocorticoids are also known to cause abnormal metabolism in the liver, and Cushing’s syndrome is associated with increased hepatic fat accumulation (62). Accordingly, lipid staining in the animal model revealed a higher fat content in livers of corticosteroid-treated rats as compared to controls. Unexpectedly, however, hepatic AMPK activity was significantly higher in corticosteroid-treated rats compared to sucrose-treated controls. Interestingly, a recent report in rats and mice subcutaneously injected with dexamethasone for 5 days and in primary cultured hepatocytes had shown a similar finding with significant up-regulation of hepatic AMPK expression (133). Recent data have shown that acute forced hepatic over-expression of AMPK leads to a significant accumulation of lipids within the liver (17), as both glycolysis and gluconeogenesis are suppressed and lipid oxidation facilitated (20); the resultant shift to lipid oxidation as a source of fuel induces a net flux of fatty acids into the liver (17). As I have also shown that decreased visceral fat AMPK activity shifts this organ to enhanced lipogenesis as well as enhanced lipolysis, there is thus an efflux of fatty acids from the adipose depots as well as net hepatic uptake: the increased flux of centripetal hepatic lipid delivery may account for the significant hepatic steatosis characteristic of Cushing’s syndrome (62). While in a model of short-term over-expression of AMPK in the liver total adipose tissue fell as lipids were transferred to the liver (17), in Cushing’s syndrome this would be counteracted by the fall in adipose tissue AMPK and thus increased local adipose tissue lipogenesis. While the decrease in hepatic gluconeogenesis would alone be likely to lower circulating blood glucose levels, leading to a fall in circulating insulin, the increase in blood free fatty acids consequent on increased fat lipolysis would induce a state of insulin resistance, as was indeed seen in this model, and is also characteristic of Cushing’s syndrome (122). Thus, the increased AMPK activity in the liver upon glucocorticoid treatment could be the result of the balance of local lipolysis, lipid oxidation and the flux of fatty acids into the liver (17). It has recently been shown that an increase in free fatty acids leads to fatty acid esterification, an energy demanding process, and this can increase the cellular AMP:ATP ratio and therefore AMPK activity (22). Thereby, during exercise, both AMPK activity and gluconeogenesis, an energy-requiring process that can occur at high rate, are simultaneously enhanced despite the fact that AMPK has been shown to inhibit both key gluconeogenetic and hepatic glucose production (22). 
An alternative explanation for the increased hepatic AMPK activity upon exposure to glucocorticoids might be the novel finding of the ability of SIRT1to modulate the activity of LKB1 (134). These authors found that factors that activate SIRT1 lead to deacetylation of one or more key lysine residues on LKB1. This in turn increases its kinase activity, and leads to the phosphorylation and activation of AMPK and possibly other LKB1 targets. SIRT1 protein levels are up-regulated by various factors, e.g. starvation or nitric oxide (135). The effect of glucocorticoids on SIRT1 expression and protein levels in the liver is not known. However, adipogenesis induced by dexamethasone and insulin has been shown to up-regulate SIRT1 in 3T3-L1 fibroblasts (136). 

In contrast to previous findings in primary cultured rat hepatocytes (133), I found that dexamethasone treatment significantly increased AMPK activity in a human hepatoma cell line after 6 hours, but not after 24 hours. This suggests that corticosteroids enhance liver AMPK activity through a time-dependent effect. Glucocorticoids are known to cause different, sometimes opposite, effects in short-term compared to longer term treatments. For example, acute corticosteroids cause growth hormone release while chronic glucocorticoid excess reduces growth hormone and IGF-1 levels (137, 138). 

Obesity in Cushing’s disease develops in part by increased food consumption, mainly of carbohydrates and proteins (60). The observation that glucocorticoids induce food intake are related to an action of these hormones within the central nervous system (139, 140). This suggestion is in keeping with observations made in rodents and humans that glucocorticoids stimulate food intake (60, 141), a complex process that is controlled by both hypothalamic and peripheral factors. AMPK is expressed in neurons of the central nervous system (39). Recent studies, including our own, have shown that AMPK plays an important role in nutritional sensing and feeding behaviour regulation in the hypothalamus (40-42), with connections between hormones affecting appetite and metabolism and the AMPK system (41, 42, 142, 143). Pharmacological activation of AMPK in the hypothalamus stimulates food intake (41-43). Administration of glucose inhibits hypothalamic AMPK activity (40, 41), and I therefore  analysed three groups of animals with the saline-drinking group being an appropriate control for the influence of sucrose on hypothalamic AMPK activity. In this experiment, sucrose inhibited hypothalamic AMPK activity, as shown by a significantly lower hypothalamic AMPK activity in sucrose-drinking compared to saline drinking control rats. Corticosterone administration however counteracted the sucrose effects and increased hypothalamic AMPK activity to levels comparable to saline drinking animals. This suggests that corticosterone treated rats had a specific increase in AMPK activity, which accordingly leads to a trend to an increased total calorie intake. Because of their marked catabolism, the experimental rats did not increase their net weight, in spite of the increase in adipose tissue. 

2-AG is the most abundant endocannabinoid found in the brain. Recently, biochemical analysis of hypothalamic slices treated with dexamethasone revealed that glucocorticoids induced a rapid increase in the endocannabinoid levels 2-AG and AEA via a rapid, membrane receptor-dependent mechanism (72). In addition, chronic glucocorticosteroid treatment increased the 2-AG content of the rat amygdala (144). I now show increased content of 2-AG in the hypothalamus of corticosterone-treated rats as compared to control rats; as it has been shown that cannabinoids have a direct effect on hypothalamic AMPK activity (43), this provides a possible mechanism for the orexigenic effect of glucocorticoids. I therefore suggest that glucocorticoids increase appetite via endocannabinoids in the hypothalamus, although the involvement of other mediators, such as neuropeptide Y (NPY), AGRP and POMS, may also play a role (145). Corticosteroid implants in mice have also shown to increase the hypothalamic expression of both AGRP, which is orexigenic, as well the satiety peptide POMC (146). 

The anabolic effect of chronic hypercortisolism on adipose tissue is opposed by a catabolic effect on muscle. The increase in plasma cortisol concentration contributes to the hypermetabolic state characterised by increased energy expenditure, accelerated net protein breakdown and negative nitrogen balance (60). A previous study using glucose infusions to induce insulin resistance showed a decrease in AMPK activity of dark muscle but not in white muscle, with a more pronounced change in the 2 subunit (147). In my model of corticosteroid-induced insulin resistance I could not detect any effect of corticosteroids on skeletal muscle AMPK activity, neither on white nor on dark muscle. Assessment of the AMPK 2 subunit AMPK activity did also not reveal a significant difference between the three groups, suggesting that AMPK is not modulated by glucocorticoids in skeletal muscle. 
However, in cardiac muscle corticosterone induced a significant decrease in AMPK activity. Clinically, corticosteroids usually cause hypertension and left ventricular hypertrophy, atherosclerosis and myocardial ischaemia (148). Nevertheless, the myocardial abnormalities, left ventricular systolic and diastolic function, are not fully explained by the secondary changes due to insulin resistance and hypertension, and suggest a direct effect of excess cortisol on the myocardium (64, 65). AMPK is generally activated by ischaemia in the heart, leading to increased glucose uptake and phosphorylation of the heart specific 6-phosphofructo-2-kinase, which activates production of ATP by glycolysis under anaerobic conditions. Activation of AMPK during ischaemia (149) also lowers malonyl-CoA and thus increases ATP generation via fatty acid oxidation during reperfusion (150). Recent results using mice expressing a dominant-negative AMPK mutant in the heart suggest that the presence of AMPK protects cardiac ATP levels, and reduces infarct size and damage to myocytes during ischaemia (151). We observed a reduction of AMPK activity in heart muscle. The decrease in myocardial AMPK activity induced by a glucocorticoid suggests that the deleterious effect of corticosteroids on the heart could at least in part be mediated by the decrease in AMPK activity. 

It has been suggested that corticosteroids provide the link between stress, the metabolic syndrome and mortality (152), and may also mediate the adverse effects of low birth weight in programming obesity and insulin resistance in later life (153). Support for a link between the metabolic syndrome, obesity and AMPK from these data could aid in the development of new treatments for these highly prevalent disorders. A recognised link between AMPK and cortisol could improve the development of safer forms of corticosteroid therapy, and improve therapeutic possibilities for the treatment of Cushing's syndrome. In particular, the demonstration of the discordant effects of corticosteroids on hypothalamic, adipose, hepatic and cardiac tissues may suggest a pharmacological role for tissue-specific modulation of AMPK activity. This may be important in both reversal of the deleterious metabolic consequences of excessive glucocorticoid activity, as, for example, bisphosphonates play in glucocorticoid-induced osteoporosis, but may also be relevant to the much bigger problem of the metabolic syndrome. If at least some of these effects are also mediated by tonic or phasic increases in pituitary-adrenal activity (152, 153), tissue-selective modulation of AMPK could prove to be of major therapeutic importance.  

Metformin is a mainstay of therapy in the treatment of type 2 diabetes. The ability of metformin to lower blood glucose requires LKB1 and AMPK signals (154, 155). In this study, metformin reversed the effects of corticosteroids on AMPK in vitro both in primary hypothalamic cell culture as well as in adipocytes, suggesting that metformin and glucocorticoids influence the AMPK signalling pathway in opposite ways and that the metformin effect is able to override the cortisol effect. In addition, metformin treatment was also able to reverse the effects of dexamethasone on two AMPK-regulated processes in human adipocytes: FAS mRNA expression and glucose uptake. These data suggest that metformin treatment could be beneficial in patients with Cushing’s syndrome in the treatment of their metabolic complications. The opposite effect of metformin on hypothalamic AMPK compared to peripheral tissues has recently been shown (156).
Several questions in our study remain unanswered. First, the majority or our data are only the correlation between changes in AMPK activity and corticosteroid-induced metabolic changes and gene expression. We do not show data about the potential mechanism for changes in AMPK activity in response to corticosterone in each tissue. 
To examine which metabolic abnormalities and changes in gene expression in response to corticosterone are dependent on AMPK, it would be necessary to study an AMPK KO model. However, since AMPK KO animals already exhibit metabolic changes similar to those seen in insulin resistant states like Cushing’s disease, this model can, unfortunately, not be used to answer our questions (157, 158). To study potential mechanisms for the changes in AMPK activity in response to corticosterone, we performed western blotting in mesenchymal adipose tissue of the corticosterone treated rats as compared to control rats for the main upstream kinases of AMPK, i.e. LKB1 and CaMKK. The results show that visceral fat tissue has reduced expression of CaMKKβ (to 69.2 ± 5.4% of saline control, P<0.05) whereas no significant differences were detected in LKB1 and CaMKKβ in subcutaneous adipose tissue. This suggests that the effect of corticosteroids on AMPK is via the upstream kinase CaMKKβ in visceral fat tissue. 
Furthermore, we performed experiments with the glucocorticoid receptor antagonist RU486, a well known antagonist of the glucocorticoid receptor. We were not able to block the effects of corticosteroids on AMPK, but the results were inconsistent and we did not follow up further these experiments. Although being a receptor antagonist, RU486 has been shown to induce receptor translocation to the nucleus and it should therefore be regarded as partial agonist (159). This could be one possible explanation for the inconsistent and unexpected results seen in our experiments with RU486. 
Second, it remains an open question whether the observed effects of corticosteroids on AMPK are genomic or non-genomic effects, respectively. As mentioned above, RU486 did not change the effects of corticosteroids on AMPK. Furthermore, we used a high dose of dexamethasone (10-6M) which might have been even higher taking into account the likelihood of endogenous steroids in fetal calf serum. This dose is clearly supraphysiological and at the upper limit of the dose-response curve. Taken together, this could rather point to a non-genomic action of corticosteroids on AMPK, but this question has to be further investigated. 
Third, we can not conclude whether the observed effects of corticosteroids on AMPK activity is of direct or of indirect nature. Our data with an effect of dexamethasone on AMPK activity in cells may point to a direct effect of corticosteroids on AMPK. However, these results are not necessarily indicative for a direct effect but could also be indirect and mediated by intermediary signalling pathways. 
Forth, it remains unclear whether glucocorticoids influenced the transcriptional level of AMPK or rather protein activity. In our study, we measured mRNA levels of AMPK subunit α1, where we did not find significant changes upon glucocorticoid treatment, but we did not assess the mRNA expression of α2, β or γ subunits. The levels of protein expression were not determined, therefore it is still possible that despite lack of mRNA changes, protein levels could be regulated and the changes in enzyme activity is not just due to the different phosphorylation status of the peptide but rather the different amount of total and phiosphorylated AMPK protein in the cell. 

One possible limitation of the design of our study is that animals treated with corticosteroids were adrenalectomized, in contrast to the two control groups. One could argue that the changes in AMPK activity seen in our experiment are not because of corticosteroid treatment but because of a lack of catecholamines. Indeed, catecholamines stimulate AMPK activity in rat adipocytes (160), and a lack of catecholamines could, thus, have the opposite effect of a reduced AMPK activity, an effect which was seen in our study in adipose tissue. However, preliminary results of experiments in mice which were treated with corticosteroids without previous adrenalectomy show similar results in AMPK activity in response to glucocorticoid treatment compared to the present study with rats, making the lack of catecholamines an improbable confounder. We did not perform a proper power analysis for the in vivo experiment. However, we based the number of animals used on the studies of prof Mary Dallman, San Francisco (94, 95) who had a significant increase in corticosterone levels as well as in visceral fat mass and other metabolic parameters with a similar number of rats. 

Project B

The standardized model in the first study for studying cortisol responsivity to acute major surgical stress shows two main findings. First, serum FC levels show a more pronounced increase with major stress as compared to TC levels followed by a more pronounced decrease after resolution of major stress. However, the second critical finding is that while TC levels show a similar increase with major stress as compared to ACTH stimulation, the increase in FC was more pronounced than with the surgical stress. 
The purpose of a stimulation test of the hypothalamo-pituitary-adrenal (HPA) axis is to predict whether, on demand, the adrenals will be able to produce the cortisol levels needed – those actually found in severe stress (92). In normal subjects, the ACTH test correctly seems to predict the TC levels that will be reached under severe stress in most cases (91). Conversely, our results suggest that the serum TC response to ACTH does not accurately reflect maximal HPA axis reserve which is produced upon major stress in terms of FC, the biologically active agent. Our study raises doubts regarding the accuracy of the TC measurement basally and after ACTH testing for diagnosing relative adrenal insufficiency in patients undergoing severe stress. However, whether this more pronounced increase is of pathophysiological relevance remains to be seen. Surgery in our study was taken as the prototype stimulus for stress as it can readily be assessed experimentally. By extrapolation, this may include other forms of stress (89). Of course, CABG as an acute stress is not necessarily equivalent to the more chronic forms of stress in critical illness or sepsis. Nevertheless, if these findings were to be confirmed in a cohort of patients with severe sepsis, some patients could be wrongly diagnosed in terms of their adrenal reserve based on ACTH testing. The concept of ‘relative adrenal insufficiency’ in such patients has already been challenged (74, 89, 161, 162). 
In the original studies on the use of a pharmacological test of cortisol reserve, using insulin-induced hypoglycaemia as a surrogate for responsivity to surgical stress, it was shown that the peak cortisol response to insulin could be used to predict those patients who might have a subnormal cortisol response to surgical stress (163-166). As the lowest level of cortisol seen in any patient undergoing major surgery was >20g/dl (~550nmol/l), patients showing this level of cortisol in response to insulin-induced hypoglycaemia were assumed not to require corticosteroid cover during surgery. More recently, many groups have used pharmacological stimulation with synthetic ACTH as a more convenient surrogate for the insulin test (167-169). In the present study, as in many previous ones, the ACTH test using 250g of synthetic ACTH showed similar peak levels of TC to ACTH and surgery, so it might be assumed that patients also showing such a response to synthetic ACTH will respond adequately to surgery with identical levels.  However, the current data suggest that, in terms of the biologically-active free cortisol, ACTH stimulation may not translate to surgical responsivity, and it sheds doubt as to the clinical validity of this test in this cohort. Further studies assessing serum FC responses to insulin-induced hypoglycaemia will be of considerable interest. However, while the insulin-induced hypoglycaemia test may be considered the gold standard in the assessment of adrenal function, it is impractical and unsafe in the setting of acute stress such as major surgery (89). 

CBG has a low capacity and high affinity, whereas albumin has a high capacity and low affinity for binding cortisol (89). Hypoalbuminaemia is defined as a serum albumin concentration of <25g/l. A steady decrease in the percent bound cortisol is noted when albumin concentrations in plasma were less than 20g/l (170). In these surgical patients with major stress, 70% of the patients had a serum albumin concentration below this threshold value. Accordingly, the calculated free cortisol index increased by 130% as compared to an almost 400% increase in free cortisol, underlining that not only variations in CBG but also in serum albumin concentrations may have a major impact on free cortisol, and should not be neglected in the management of surgical patients with major stress. In this context, it is not surprising that free cortisol levels showed a good albeit not perfect correlation with the calculated free cortisol index in our study. The aetiology of hypoalbuminaemia in surgery and especially cardiac by-pass surgery is complex and undoubtedly involves a dilution factor (171). This albumin lowering is caused in a large part by the volume of intravenous fluids used and blood loss (172), in addition to other potential mechanisms including increased capillary leakage, and altered intravascular and tissue albumin distribution (173, 174). Thus, it could be argued that this surgical procedure cannot be used as a surrogate stress for evaluating cortisol levels. As a limitation of our study, I did not assess the exact amount of fluid administration and blood loss. However, this dilution is not a unique finding to cardiac bypass surgery, but is also seen to a similar extent in abdominal surgery (172) or sepsis (175). In addition, despite dilutional effects on circulating proteins a coronary artery by-pass procedure produces an acute phase reaction of the same magnitude as sepsis, major trauma and burns (176, 177). 
The newly developed assay to measure FC has certain advantages over other commercially available assays. Firstly, equilibrium dialysis is generally seen as a reference method for measuring free cortisol as no bound cortisol can be measured by virtue of the dialysis membrane. Secondly, the cost of setting up this assay is only a fraction of existing methods to measure FC (178-180). In addition, as noted above, alternative methods to calculate FC (e.g. free cortisol index, Coolen’s equation) do not take into account all of the proteins to which cortisol can potentially bind. A simpler, less time consuming alternative might be the assessment of salivary cortisol as it has been proposed as a valuable measure of FC (181, 182). Indeed, recent data suggest the usefulness of salivary cortisol in critical illness (183). 
As parameters of the systemic inflammatory response, I measured C-reactive protein and procalcitonin in the surgical patients. Both showed a significant increase with surgery and a significant correlation with TC and FC levels. The interactions between inflammatory cytokines and related peptides are complex, with evidence that such cytokines may act directly on the hypothalamus to increase the secretion of corticotrophin releasing hormone and vasopressin, on the pituitary to stimulate ACTH release and even directly on the adrenal via an ACTH-independent process (184, 185). 
As a limitation of our study, we pooled data of the 1µg and 250µg ACTH test. However, the results when only taking the 1ug ACTH test are similar to those after 250µg. The number of patients tested with 1µg was very limited, and to exclude the 250µg dose would have severely limited the power of our study to draw general conclusions. In addition, we compared the free and total cortisol levels after 1 and 250µg ACTH stimulation (at 30 minutes). Both levels were significantly higher after 250ug ACTH compared to stimulation with 1ug ACTH. The difference between free and total cortisol levels, however, was not significant. Thus, it seems improbable that the results would look different when only 1 or only 250µg tests would have been included in the analysis. 
In addition, there are considerable differences in the patient characteristics between groups A to C with regards to gender, age and BMI, possibly introducing a bias into our results. 
In conclusion, based on these data, FC concentrations measured with a newly developed assay provide a more accurate reflection of circulating glucocorticoids than TC levels. The findings in support of this proposition are: 1) with major stress, FC, but not TC, levels increase to a greater extent than after pharmacological ACTH testing; 2) basal FC levels were several-fold more elevated than TC levels after extubation; and 3) after resolution of major stress, basal FC levels fell promptly, but TC levels remained significantly more elevated. These results also raise doubts as the utility of some pharmacological tests of HPA reserve.

Based on these findings I hypothesised that FC is a better prognostic measure to predict outcome in acute illness as compared to TC. Thus, I tested the hypothesis that our FC assay in a well defined cohort of 278 patients with community-acquired pneumonia. This study revealed the following findings: first, both, TC and FC cortisol concentrations measured on presentation predict the severity and outcome of CAP. Second, the prognostic accuracy of cortisol levels is as high as the PSI and higher as compared to commonly measured laboratory parameters. However third, the prognostic accuracy of free cortisol levels is not superior to that of total cortisol in this paradigm. 

The release of cortisol in acute illness is essential for cardiovascular, metabolic and immunological homeostasis. The rationale for a presumed prognostic value of cortisol is mainly due to the positive correlation of the individual stress level associated with the illness. A higher level of pro-inflammatory cytokines in patients with worse outcome, i.e. non-survivors, could additionally lead to a more pronounced increase of cortisol as the strongest known natural inhibitor of inflammation (186). However, levels of C-reactive protein, as one example of an inflammatory mediator, were similar in survivors and non-survivors. Indeed, in critically ill patients a strong association of cortisol with outcome has previously been reported (77-83). Conversely, very low unstimulated cortisol levels in septic patients can also predict absolute or relative adrenal insufficiency, respectively (92, 128). Based on this study, serum cortisol concentrations are also a prognostic parameter in CAP, a milder form of infection and a major precursor of sepsis. Interestingly, in this study low cortisol levels were not associated with poor outcome in the  study cohort. Indeed, the mortality in patients with relatively low levels was around half of that in the cohort as a whole, although possibly due to the small numbers this did not attain statistical significance. It is possible that in this series the absence of patients on any form of adrenolytic drug excluded the possibility that there was any form of iatrogenic, and hence deleterious, hypoadrenalism. Alternatively, there may be two factors in operation, one directly associating serum cortisol with mortality, and one operating at low cortisol levels to increase mortality, such that at low cortisol levels these cancel each other out. Whatever the explanation, the overriding factor associated with poor outcome was increased cortisol, how ever it was measured. Indeed, there is a debate concerning the definition of relative adrenal insufficiency, its treatment and the identification of patients at risk (74). In a small study, low-dose hydrocortisone infusion appeared to be beneficial (187), however, these preliminary data need to confirmed in a larger study before it can be recommended. Our findings of an association of high cortisol levels with worse outcome question the rationale of hydrocortisone treatment in patients with CAP. However, this study population was different from the population included in the study by Confalonieri et al. (187). While they included mainly mechanically ventilated patients on the ICU, I investigated patients at presentation to the Emergency department (ED) including all classes of PSI. 

In general, it is assumed that the biologically active fraction of cortisol to which tissues are exposed is free cortisol. Specifically, in critically ill patients there is a fall in binding proteins such that total cortisol levels no longer accurately reflect the free fraction (88, 89). Free cortisol in this study was no better predictor of outcome than total cortisol levels. However, while albumin levels were slightly lower in non-survivors as compared to survivors of CAP, the binding protein levels did not correlate strongly with pneumonia severity as assessed with the PSI. This is in contrast to the previous study including patients with major surgical stress. Therefore, in less critically ill patients such as CAP patients, fluctuations of cortisol binding proteins (such as albumin and CBG) may become less relevant, diminishing any potential advantages of an assay measuring the free hormone. Only 5% of the patients in this study had serum albumin levels below 20g/l and only 19% below 25g/l. Taken together, these findings suggest that the prediction of outcome is not primarily related to the free fraction of cortisol in CAP. 

A key decision for a clinician is whether to admit a patient with CAP (188). This decision is complex and depends on many variables, including estimates of the severity of illness. It often relies on the clinician’s judgment; however, the interpretation of clinical signs and symptoms lacks standardization and validation and is prone to interobserver variability (189, 190). In addition, physicians continue to be conservative and commonly overestimate the risk of death in patients with CAP (191). Clinical signs such as body temperature or routinely-used laboratory parameters (i.e. C-reactive protein or leukocyte count) are only of very limited value to predict disease severity in CAP (192). Thus, clinical judgment alone can be misleading in estimating disease severity, thereby leading to under- as well as overestimation of the severity of CAP. For this reason, prognostic scoring rules have been developed to predict severity of CAP and outcome with the PSI being a well-validated prognostic classification score (116-120). Limitations of the PSI include a potential overemphasis on age and the fact that, for clinical ease, the PSI dichotomizes continuous values such as heart rate or oxygen saturation into normal and abnormal values. The intra-observer variation of the PSI is reported to be around 10%, with most patients misclassified into the high-risk classes IV and V (193). In addition, the PSI is best validated for assessing patients with a low mortality risk who may be suitable for home management rather than for those with severe CAP at the time of hospital presentation (120). The major limitation for the routine use of the PSI, however, is its laborious calculation. In a recent study validating the predictive potential of different indices in 731 patients with CAP the PSI score could only be calculated in 70% of all patients (194) restricting its widespread adoption. The American Thoracic Society (ATS) guidelines do not offer any algorithm for the clinical assessment of disease severity (115, 195). In this context, there is need for readily measurable parameters predicting the severity level and outcome of CAP. According to the present data, the simple measurement of total cortisol provides equivalent prognostic information as the complex 20-variable severity index. This is remarkable. It therefore represents an additional and easy-to-determine prognostic tool. As a new indicator for those patients with a worse prognosis, it allows such patients to be targeted for more intensive therapy. As the combination of cortisol measurement and the PSI score tended to have an even higher prognostic accuracy, it is advisable to utilize several clinical and laboratory parameters, which may mirror different physiological aspects, in the complex task of prognostic assessment and treatment decisions. 

C-reactive protein has been reported to be a useful marker for predicting disease severity in patients with pneumonia (196). In contrast, in this study C-reactive protein could not differentiate between different severities of CAP, as defined by the PSI, and was not a significant independent predictor of outcome. It should be recognised that C-reactive protein is a rather non-specific marker of acute-phase inflammation, and is thus subject to the influence of many other factors. Interleukin-6 (IL-6), a key stimulator of hepatic C-reactive protein release, has also been suggested as a useful marker in the determination of the severity of CAP (197). Measurement  of plasma cytokines such as IL-6 is, however, a difficult and cumbersome process, partly because of the short plasma half-life and the presence of blocking factors (198). Most recently, D-Dimers have also been proposed as prognostic parameter in CAP (199), but these were not measured in this study. Finally, several groups have proposed that procalcitonin  is a novel and useful marker of disease severity in community-acquired pneumonia (121, 200). However, the present data suggest rather that procalcitonin is useful as a diagnostic and not primarily a prognostic tool able to guide decisions on antibiotic therapy (121, 123). 

The following limitations of this study should be mentioned. First, this study had not been prospectively designed to utilise cortisol concentrations as a primary endpoint, and only single presentation cortisol levels were measured (121). Second, serial cortisol levels show large variations during the day (201), although during infective illness the circadian pattern of cortisol is usually lost (75). In the present study, serum cortisol levels were measured at the time of presentation, i.e. at different time points during the day, which could limit the predictive accuracy of a single cortisol value on presentation to the hospital. A standardised cortisol value at the same time in all patients would most probably have had an even higher prognostic accuracy. It is also possible that serial measurements over the course of the disease may add prognostic information, and show differences in the value of free and total cortisol (202). 
Third, I did not assess adrenal function based on the response to injection of synthetic adrenocorticotropin, as used in other studies. However, since these patients were patients without septic shock, it seems unlikely that they experienced relative adrenal insufficiency. Indeed, as noted above, there was actually a trend for decreased mortality in patients with relatively low serum cortisol levels. 

In conclusion, these findings indicate that cortisol levels are significant independent predictors of outcome in milder forms of illness and acute infection such as CAP; the prognostic accuracy of total and free cortisol is as high as the PSI and better as compared to routinely measured laboratory parameters. Free cortisol levels are not superior to total cortisol levels.
 



7.	OUTLOOK

Based on these results I now plan to initiate two multicentre randomised placebo-controlled intervention studies which are briefly described below: 

1)	Prevention of metabolic complications of glucocorticoid excess
Many of the changes seen in GC excess correspond to metabolic steps regulated by AMPK. We have shown that corticosterone treatment changes AMPK activity in a tissue-specific manner in adipose, liver, myocardial and hypothalamic tissue (205). In addition, the GC effect on AMPK can be reversed by metformin treatment in primary human adipocyte and primary rat hypothalamic cells in vitro. The planned study will explore this effect in a proof-of-concept human study. It is suggested that metformin is able to prevent the metabolic complications of glucocorticoids. 
Briefly, we will recruit patients (18-75y) with rheumatic conditions requiring GC treatment (e.g. rheumatoid arthritis, giant cell arteritis, polymyalgia rheumatica) into a randomised, double-blind, placebo-controlled trial. Patients who are about to start glucocorticoid treatment predictably for ≥12 weeks at a ≥10mg/d prednisolone (or equivalent) dose who consent to participate in this study will be randomly assigned to receive either placebo or metformin at the maximum tolerated dose with a minimum of 850 mg bd for 12 weeks. Metformin treatment will be started gradually (as standard practice) to avoid gastrointestinal side effects and the full dose will be reached by day 10. Patients will have a full clinical assessment before the start of the metformin treatment and at the end of the 12 weeks treatment period. The primary study endpoint will be a change in visceral to subcutaneous fat area ratio as assessed by CT. Secondary endpoints will be HOMA-index, body weight, waist/hip ratio, blood pressure, LDL&HDL cholesterol, triglycerides, homocysteine, fibrinogen, liver fat content, carotid intima media thickness, left ventricular mass index, and an oral glucose tolerance test. 

2)	Corticosteroids to improve outcome in community-acquired pneumonia
An intact hypothalamo-pituitary-adrenal axis with an effective intracellular anti-inflammatory activity of glucocorticoids is indispensable for host survival during stress upon exposure to an infectious agent. Community-acquired pneumonia (CAP) is characterised by significant mortality and increased circulating inflammatory cytokines. The use of corticosteroids in patients with CAP is inconclusive.
The aim of this study will be to compare a treatment with 7 days of corticosteroids with placebo in patients with CAP. 
All patients 18 years or older hospitalized with CAP will be included and randomized 1:1 either to corticosteroid treatment or to placebo. Excluded are patients unlikely to comply; severe immuno-suppression; nosocomial pneumonia; acute burn injury; major gastrointestinal bleed within 3 months of the current hospitalization, a condition requiring more than 0.5mg/kg/d prednisone equivalent; pregnancy and breast feeding. 
The primary endpoint will be time to clinical stability. Secondary endpoints will be duration of hospitalization (time to effective hospital discharge and time to earliest possible hospital discharge, respectively), duration of intravenous and total antibiotic treatment, disease activity scores, side effects from corticosteroids, value of adrenal function testing, DHEA and cortisol to identifying those patients who respond to corticosteroid treatment, effect of corticosteroid treatment on laboratory markers of infection (i.e. procalcitonin, C-reactive protein, interleukin and cytokine levels), comparison of free and total cortisol levels on admission to predict survival and to identify patients profiting from corticosteroid treatment. 
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10. APPENDIX – Laboratory protocols
10.1. Primary hypothalamic cultures (kindly performed by Francois Pralong and co-workers)
Poly-D-Lysine
1.	Plate X wells or Petri dishes with poly-D-lysine for 48H
2.	Rinse 1 X with sterile water (same volume of poly-D-lysine) and once more with solution A (PBS + Glucose + Pen/Strepto) (same volume of poly-D-lysine). Leave them dry under the hood.

Hypothalamus dissection
1.	Decapitate the pregnant animal (day 18)   
2.	Cut the abdominal epidermis to reach the placenta
3.	Take 1 embryo and cut the head.
4.	Dissect the brain and place the hypothalami in 15 ml Falcon tube containing 5 ml of solution A 

Dissociation of neuronal cells
1.	Aspirate carefully the 5 ml of solution A
2.	Take a sterile Pasteur pipette. Use a sterile gray hood to aspirate
3.	Wet the pipette with solution A (otherwise tissue sticks) and resuspend the remaining pellet with 3 ml of solution A
4.	Dissociate by passing through the Pasteur pipette 5 times
5.	Decant for 2 min and transfer the supernatant to a clean 15 ml tube
6.	Repeat steps 4 and 5 and add to the first supernatant

	Note: It is not necessary to dissociate all small pieces. It is normal to have pieces resistant to dissociation which represent fibrous tissue that must be eliminated.
	
7.	Complete volume to 12 ml with solution A
8.	Centrifuge 7 min at 100g
9.	Aspirate supernatant
10.	Resuspend the cellular pellet carefully in X ml of NBB27 ((Neurobasal medium + (B27, glutamine, glutamate, PSN,)) with a 10 ml pipette
11.	Make a 1/2 dilution in trypan blue and count alive cells 
12.	Adjust the X ml to the require volume considering the surface and liquid volume/well or dish (3 ml/well for 6 wells plate or 35mm dish; about 450 000 cells/well)
13.	 48h after plating add araC to a final concentration of 2 M (to avoid astrocytes proliferation)
14.	48h after araC addition change medium. Take out half volume of the medium and replace with the same amount of NBB27 ((Neurobasal medium + (B27, glutamine, whithout glutamate, PSN))
15.	Change medium 1X (<500 cell/mm2) or 2X (> 500 cell/mm2) a week

10.2. Human mesenchymal stem cell (MSC)-derived adipocytes (performed in Basel, Switzerland)
Isolation and expansion of MSC-derived adipocytes: 
Bone marrow aspirates (20 – 40 ml) are obtained from healthy donors (18 – 63 yr) during routine orthopedic surgical procedures, in accordance with the local ethical committee (University Hospital Basel) and after informed consent.
After diluting the marrow aspirates with phosphate buffer saline (PBS) at a ratio of 1:4, nucleated cells are isolated using a density gradient solution (Histopaque, Sigma Chemical, Buchs, CH). The cells are cultured in Minimum Essential Medium (MEM) α medium with 1.0g/L glucose containing 10% fetal bovine serum (FBS), 1% HEPES (1M), 1% sodium pyruvate MEM 100 mM, 1% penicillin-streptomycin glutamate (10,000 U/ml penicillin; 10,000 µg/mL streptomycin) (all from Invitrogen AG, Basel, CH). Nucleated cells are plated at a density of 100,000 cells/cm2 in the medium supplemented with 5 ng/mL fibroblast growth factor-2 (FGF, R&D Systems, Wiesbaden, D) and cultured in a humidified incubator at 37°C, 5% CO2. FGF is supplemented in order to enrich the fraction of true progenitor cells [24]. MSC are cultured in 175cm2 Flasks (Becton Dickinson AG, Basel, CH), allowing attachment. Medium is changed twice a week. MSC are selected on the basis of adhesion and proliferation on the plastic substrate.

MSC culture
After the 3rd passage medium is changed to DMEM with glucose 25mM supplemented with 10% heat inactivated FBS, 5 ng/mL FGF, 1% sodium pyruvate MEM 100 mM and 1% penicillin/streptomycin 5000 U/mL (all from Invitrogen AG, Basel, CH). Media and supplements are changed every 72 h. At a confluency of 95%, cells are collected using trypsin (Invitrogen AG, Basel, CH) and washed twice with serum-free DMEM/F12 medium.

Medium used for expansion of MSC’s: 
DMEM 10% FCS-MEDIUM

-750 ml	D-MEM  +4500mg/l Glucose
		CAMBREX 12-604F ( Kühlraum )
		(FAX 0800 83 86 20 )
- 8.3 ml	Sodium Pyruvate MEM 100MM
		Gibco Nr. 11360-039 ( Kühlschrank Gang )
- 8.3 ml	Penicillin / Streptomycin
		Gibco BRL No 15140-122 ( -20ºC Gang )
-83.25 ml	Foetal Bovine Serum
(thaw in 37ºC, 30' in 56ºC, fill in and keep in -20ºC)
-150 µl	            FGF  ( 5 ng)

10.3. Glucose uptake in MSC’s
Day 1: remove differentiation medium. Wash cells 3 times with warm PBS1x (RT) and keep cells in DMEM-F-12 containing 5mM of glucose and 3% FBS. 
Day 3: stimulate cells: 
t=0 minutes, add 100nM of insulin to one half of the cells. 
t=20min add 1μC 2-deoxy-D-[3H(G)] deoxy-glucose (Perkin Elmer, Boston, MA) to all cells 
t=35min wash the cells 3 times in ice-cold PBS and lyse them in 0.1% sodium dodecylsulphate (SDS). 
Day 4: 	add 6l of actrapid (dilution 1:100 with medium)
        	incubate for 20min at 37°C
        	add 5l of tracer (H3 dilution 1:10 with medium)
        	incubate for 15min at 37°C
        	wash 3x times with PBS1x (ice cold)
        	add 500l SDS 0,1% (ice cold)
        	transfer to scintillation tubes
       	add 2.5ml scintillation-fluid (PICO FLUOR 15 from Perkin Elmer)
        	shake well 
measure radioactivity with beta-counter


10.4. Buffers and working solutions
HEPES-Brij buffer: (can be kept for a few days at 4C, otherwise store at -20C)

50mM Na HEPES, pH 7.4,
1mM dithiothreitol (DTT)
0.02% Brij-35 

100mM unlabeled ATP:  (store at -20C)

1mM AMP:  (store at -20C)
SAMS peptide:  (store at -20C)
1% v/v ortophosphoric acid

Lysis buffer for cell culture (not for hypothalamic cell lines): (store at -20C in aliquots)

50mM Tris-HCl, pH at 7.4 at 4 C
50mM NaF, 
5mM Na pyrophosphate
1mM EDTA
1mM EGTA (No EGTA because apparently interferes with BCA kit)
250mM mannitol
1% (v/v) Triton X-100
1mM DTT
1mM benzamidine
0.1mM phenylmethane sulfonyl fluoride (PMSF)
5ug/ml soybean trypsin inhibitor (SBTI)

Lysis buffer for Hypothalamus (cell line and tissue):   (store at -20C in aliquots)

50mM Tris-HCl, pH at 7.4 at 4 C
50mM NaF, 
5mM Na pyrophosphate
1mM EDTA
1mM EGTA (No EGTA because apparently interferes with BCA kit)
250mM sucrose
1% (v/v) Triton X-100
1mM DTT
1mM benzamidine
0.1mM phenylmethane sulfonyl fluoride (PMSF)
5ug/ml soybean trypsin inhibitor (SBTI)

Lysis buffer for Tissues (e.g. adipose, muscle, liver): (store at -20C in aliquots)

50mM Tris-HCl, pH at 7.4 at 4 C
50mM NaF, 
5mM Na pyrophosphate
1mM EDTA
1mM EGTA (No EGTA because apparently interferes with BCA kit)
10% (v/v) glycerol
1% (v/v) Triton X-100
1mM DTT
1mM benzamidine
1mM phenylmethane sulfonyl fluoride (PMSF)
5ug/ml soybean trypsin inhibitor (SBTI)

Immunoprecipitation buffer: (store at -20C)

50mM Tris-HCl, pH at 7.4 at 4 C
150mM NaCl
50mM NaF, 
5mM Na pyrophosphate
1mM EDTA
1mM EGTA
1mM DTT
0.1mM benzamidine
0.1mM phenylmethane sulfonyl fluoride (PMSF)
5 ug/ml soybean trypsin inhibitor (SBTI)

High sodium (1 M) Immunoprecipitation buffer: (store at -20C)

50mM Tris-HCl, pH at 7.4 at 4 C
150mM NaCl
50mM NaF, 
5mM Na pyrophosphate
1mM EDTA
1mM EGTA
1mM DTT
0.1mM benzamidine
mM phenylmethane sulfonyl fluoride (PMSF)
5ug/ml soybean trypsin inhibitor (SBTI)

10.5. Rapid lysis of cultured cells for kinase assay
(for cultured cells attached to the dish)
Cells are seeded in 10cm culture dishes and grown until nearly confluent. Then, the medium is removed and the cells are washed with 3x5 mL of Krebs/HEPES buffer at 37C, cells are then preincubated in 5 ml Krebs/HEPES buffer at 37°C for 30 min. The medium is removed  and replaced with a further 5ml Krebs/HEPES buffer containing any substances or treatments to be tested, and the cells incubated for appropriate times. The bulk medium is poured off, residual medium removed with a Pasteur pipette, 
the dish placed on ice (leave it on ice for 15-20min) and 0.5-1.0ml of ice-cold lysis buffer immediately added. The cells are scraped from the dish with a cell scraper and the lysate transferred to a microcentrifuge tube (tubes have been kept on ice) (the lysate is kept on ice throughout this and subsequent procedures); the lysate is centrifuged (18000g, 4C, 3min) and the supernatant transferred to a new microcentrifuge tube (which have also been kept on ice). The supernatant can be assayed immediately, or it can be snap frozen in liquid N2 and stored at -80°C for at least 2 wk prior to assay.

Treatment of cells
1. Plate out cells in the Petri dish in their usual medium (10 ml/10cm Petri dish), allow to attach but cells should be not more than 70% confluent because the mechanical stress of pushing each other can also activate basal AMPK.
2. The day after, do not change the medium, but add in that medium the treatment. To the control plate add the same amount of water. Incubate at 37°C for the appropriate time.
3. Take the plates out of the incubator. From now on keep plates always on ice. Aspirate medium. 
4. Wash plates briefly with ice-cold PBS (3ml)
5. Add ice cold lysis buffer (1ml/10cm Petri dish) and scrape cells immediately (do not leave the plates on ice for some time). Transfer the lysate to a microcentrifuge tube (tubes have been kept on ice), the lysate is kept on ice throughout this and subsequent procedures; the lysate is centrifuged (18000g, 4C, 3min) and the supernatant transferred to new microcentrifuge tubes (which have also been kept on ice). Each treatment in duplicates.

10.6. Dosage of Protein Concentration with BCA Assay
The use of Cytobuster Protein extraction reagent, lysis Buffer and RIPA require the BCA protein assay (Bradford assay can not be used with these protein extraction reagents). It is not necessary to work in sterile conditions.
Materials and solutions:
P1000, 2 P200, P20
Ice-bath
1 ml tube of 2.0 mg/ml stock BSA in the reagent required (stored at –20°C) 
Protein extraction reagent (keep at room temperature) 
BCA reagent A (keep at room temperature)
BCA reagent B (keep at room temperature)
Two 96 well/plates

Preparation of 2.0mg/ml stock BSA in the buffer used to collect protein: 

Prepare a 15mL Falcon tube with 5 ml of buffer reagent
Weigh 10mg of BSA and transfer it into the tube
Adjust the volume to obtain exactly the desired concentration of 2mg/ml and let it dissolve over night
Prepare aliquots of 1.1ml and store them at –20°C
Protocol
Prepare the BSA dilutions using the 2.0mg/ml stock BSA according to the following instructions:





Vial	Volume of Diluent(Buffer): µL	Volume and source of BSA: µl	Final BSA Concentration: µg/ml
Stock=A	0	300 of stock	2000
B	125	375 of stock	1500
C	325	325 of stock	1000
D	175	175 of B	750
E	325	325 of C	500
F	325	325 of E	250
G	325	325 of F	125
H	400	100 of G	25
I	400	100 of H	5
Blank=L	400	0	0

label each tube with the date of preparation. The standard solutions expire after 10 days. 

Pipet, in the 96 well/plate, 25µl of each BSA concentration in triplicate starting from the blank=L and then with vials I, H, G, F, E, D, C, B, A and stock=A
Pipet, in the 96 well/plate, 25µl of the unknown samples into its own microplate well. Make different dilutions of the unknown samples (for example 1:2, 1:5) and load 3 replicates of each dilution

Prepare the BCA Working Reagent (WR) mixing 50 parts of BCA Reagents A with 1 part of BCA Reagent B (50:1, Reagent A to B). Use the following formula to determinate the total volume of WR required:
(#standards + # unknowns) x (# replicates) x (volume of WR per sample) = total volume WR required. 

Add to each well 200µL of the WR and mix 
Incubate for 30minutes at 37°C in the incubator (sterile room)
After incubation, cool down the plate to room temperature (2-3min)
Measure the absorbance at 595nm on the microwell plate reader.  

Construct the standard curve on Excel (line graph)
See where the samples Optical Density (OD) lies on the standard curve
Exclude those samples that lie outside the limits of the standard curve
Choose the sample dilutions that have an OD corresponding to standard curve concentration included between 250 and 1000 g/ml
Considering the dilution factors calculate the sample concentrations and then the volume of protein extract needed for each sample

Western blot analysis can be performed on either frozen or fresh cell/tissue extracts, therefore cell extracts can be stored at –80° C or used right-away.
To prepare the samples mix the correct volume of protein extract corresponding to desired µg of proteins with a volume of protein extraction buffer in order to have equal volume for each sample. Then add an equal volume of 2X sample buffer to the volume of protein extract + the volume of protein extraction buffer.

10.7. Immunoprecipitation prior to assay 
Cell lysates can be assayed in immunoprecipitates using the anti AMPK antibodies. Complexes containing the 1 or 2 isoforms of the catalytic subunit may be precipitated specifically using anti 1 or 2 antibodies. Alternatively, total activity may be assayed using a pan  antibody, a mixture of anti 1 or 2 antibodies, or a suitable anti  or anti γ subunit antibody.
Wash 5µl x nr of samples of Protein G-sepharose with 5x1mL of IP buffer and resuspend in 400-500μl IP buffer (use pipet tips with the last 5 mm cut off to avoid trapping the beads in the tip). 
Add 5 μg x nr of samples of sheep anti-AMPK antibody to the Protein G sepharose and mix on a roller mixer for 45min at 4C
Centrifuge the slurry (18000g, 1min, 4C; I am actually centrifuging at 13000g for 2 min) and wash the pellet five times with 1 mL ice-cold IP buffer (in between each wash centrifuge again at the above conditions); resuspend the final pellet with 100 ul x nr of samples of IP buffer and divide the slurry into 100L aliquots. To each 100l aliquot add 300 g of protein and mix for 2h at 4C on a roller mix. Centrifuge the mixture (18000g, 1min, 4C or 13000g for 2min) and wash the pellet five times with 1 mL ice-cold IP buffer containing 1M NaCl (to remove nonspecifically bound proteins), wash the pellet with 3x1 mL of lysate assay buffer (in between each wash centrifuge again at the above conditions) and resuspend in 300L HEPES-Brij buffer. Divide the 300l of each sample into three aliquots of 100l each, two of which will be assayed with peptide and 1 without peptide as blank (negative control), centrifuge the aliquots and remove 80l of liquid, leaving 20l of liquid in each tube containing the equivalent of 100g of the starting protein. The tubes with 20l are stored at -20°C and are ready for the assay. It is best to assay immunoprecipitates immediately, but they can also be stored at –20°C for a few days. 

10.8. Assay of AMP-activated protein kinase  
Reaction mixtures are prepared on ice containing the following:
a. 10μL 1mM y32P ATP, 25mM MgCl2 (specific activity 250-500cpm/pmol)
b. 10μL 1mM AMP in HEPES-Brij buffer 
c. 10μL 1mM SAMS or AMRA peptide in HEPES-Brij buffer or 10 L	 HEPES-Brij buffer for the blank-negative samples
a. P32 ATP working solution (1000ul): 10μl of the freshly arrived P32 ATP 10mCi/ml +10l of cold ATP 1mM + 25 μl of MgCl2 at 1 M+955μl of Hepes-brij buffer
b. AMP 1mM
c. SAMS comes in a 562μM concentration so that it has to diluted and used at 100uM 
(17.8l of SAMS at 562μM + 82.2 of Hepes-brij buffer)
Reactions are initiated by the addition of 30μl of the Master Mix to the 20μl obtained from the Immunoprecipitation step.
Prepare also a negative reaction for AMPK: 10μl of AMPK at 10 mU/ul+10ul of Hepes-brij buffer +30μl of Master mix without SAMS.
Incubate at 30°C for 20 minutes in a shaking incubator (at 200rpm), remove 35μL and spot onto a P81 paper square. After the liquid has soaked in for 1-2 secondes, the square is dropped into a beaker containing 1% (v/v) phosphoric acid (dilute phosphoric acid of 85%: 11.76 ml of phosporic acid 85% + water up to 1000 ml).
After all incubations have been stopped the paper squares are stirred gently on a magnetic stirrer for 5 minutes, until the phosphoric acid is poured off and a second phosphoric acid wash of 5 min is performed. Then, the papers are rinsed briefly in water before soaking in acetone for another 5 minutes; then, they are laid out on a paper towel and allowed to dry for another 5 minutes. Dried filters are counted after immersing in 5 ml of Optiscint Hisafe scintillation cocktail. 
The AMPK activity is expressed in units of nanomoles of phosphate incorporated into substrate peptide per min. To determine the specific radioactivity of the ATP, spot 5 uL of P32 ATP working solution onto a paper square, dry it, and count in scintillation fluid. Keep this vial and recount it every time you count some assays using the same ATP.
Calculations: 
a. Calculate CPM positive sample-CPM negative sample
b.   Calculate nmol of ATP incorporated per min knowing the CPM obtained by 5 μl of ATP working solution =5 nmoles of ATP=> (CPM pos –CPM neg) 5/CPM 5 μl ATP working solution
c. Calculate nmoles of ATP incorporated per min per mg of protein.  
10.9. Western Blotting Protocol  
Materials required
 Tris base (Tris hydroxymethyl methylamine) [VWR; 103156X]
 Tris acid (Tris hydroxymethyl aminoethane hydrochloride) [Sigma T-3253]
 Glycine [Sigma; G7126]
 SDS (sodium dodecyl sulfate) [Sigma; L-4509]
 Methanol [VWR; 101586B]
 Sodium chloride (NaCl) [Sigma]
 Hydrochloric acid (HCl) [Sigma]
 Tween-20 (polyoxyethylene (20) sorbitan monolaurate) [VWR; 66368-B]
 2-mercaptoethanol; Sigma no. M-3148
 Skimmed (no fat) milk powder; Tesco
 Ready Gels: - SDS-PAGE Gel 10% Tris/HCl 10 wells [Bio-Rad; 161-1155] suitable for proteins 200-25kDa;
SDS-PAGE Gel 5% Tris/HCl 10 wells [Bio-Rad; 161-1213] suitable for proteins bigger than 200kDa;
10-20% Tris Tricine Gel 10 wells suitable for peptides smaller than 25kDa [Bio-Rad; 161-1162]
 Kaleidoscope Prestained Standards [Bio-Rad; 161-0324]  suitable for proteins 7-200 kDa;
 Kaleidoscope Polypeptide Standards [Bio-Rad; 161-0325] suitable for peptides 3.5-38.5kDa;
 Electrophoresis Tank [Bio-Rad; 165-3126]
 Transfer Kit [Bio-Rad]:
2 pieces of sponge, cut to size of gel
4 pieces of blotting paper [Biorad; 170-3932]
Transfer cassette and tank [Bio-Rad;  170-390]
 Detection Reagent ECL Plus Western Blotting System [Amersham; RPN2132]
 PVDF (polyvinylidene difluoride) Membrane [Amersham; RPN303F]
 Kodak Scientific Imaging Film X-OMAT [VWR no. 165-1579]
 Antibodies:
 Saran Wrap [VWR]
 Aluchef foil [VWR; 236401001]
 16.5 Tricine Running Buffer (BioRad) for small peptides (store at -200C)

Buffers and Reagents

SDS Loading Buffer (store at 40C)
1.514g Tris base (125mM), 4g SDS (sodium dodecyl suplphate) (4% w/v), 16 ml Glycerol (20% w/v), 0.02g Bromophenol Blue (0.002% w/v)
Dissolve Tris base in 100 ml of ddH2O and adjust pH to 6.8. Then add the remaining reagents and store at 40C. 
Running Buffer (store at 40C)
30.25g Tris base, 144.13g Glycine, 10g SDS.
Use 1 in 10 (i.e. 100 ml in 1000 ml ddH2O)
Transfer Buffer (store at 40C)
3.04g Tris base, 14.14g Glycine, 800 ml ddH2O, 200 ml Methanol
Dissolve Tris and glycine in H2O. Add methanol, total 1000 ml. Stir well with magnetic stirrer. Store at 40C.
Washing Buffer 1X TBS-Tween (store at 40C)
10X TBS (Tris-buffered saline):
To prepare 1 litre of 10X TBS: 24.2g Tris base, 80g NaCl, Adjust pH to 7.6 with HCl (use at 1X).
To make 1XTBS-Tween (wash buffer): 
100 ml 10XTBS + 900 ml water + 1ml Tween20 (store at room temperature)
alternatively 1X TBS, 0.1% Tween (i.e. 500 μl Tween to 500 ml 1X TBS).
Blocking Buffer (make up fresh)
2.5g Skimmed (no fat) milk, 50 ml 1X TBS-Tween
Stripping Buffer
0.985g Tris hydrochloride, 2g SDS, 781 µl 2-mercaptoethanol

Add 100 ml ddH20 to SDS and Tris, then add 2-mercaptoethanol.

Protein Sample Preparation
1. Prepare protein sample or thaw samples in ice if stored at –70˚C. Always keep samples on ice.
2. Normalise protein samples to the samples with the lowest protein concentration using Bradford Assay. Calculate the volumes required for each sample and aliquot into 0.5 ml tubes. Aliquot 10 µl of kaleidoscope marker into a tube, kept on ice. 
3. Add equal volume of SDS loading buffer to the samples. Into the marker add 10μl of SDS loading buffer. Keep on ice.
4. Heat all samples for 5 minutes at 95˚C on thermal cycle to denature proteins. Remove to ice immediately afterwards. 
SDS-PAGE Electrophoresis Preparation
5. Unwrap a pre-cast, 10% Tris-HCl gel (store at 40C) and remove the bottom edge of the plastic covering by scoring along the black line and pulling off with tweezers.
6. Loosen screws of gel chamber and insert the gel into position ensuring that the grips of the well protector at the top of the gel, faces away from you. Tighten screws gently. 7. Insert the gel chamber into the gel tank ensuring that the chamber is balanced correctly.
8. Fill the tank with 1x Running Buffer (BioRad Tris/Glycine/SDS x10, use 1 in 10) (store at room temperature).
9. Remove the well protector comb by pulling up gently using the grips on either side. Dispense samples into the wells. Max loading volume is 50μl and there are 10 wells in the Biorad gel. 
10. Run gel at 100 V for at least 1 hour or until the samples reach the wire (usually 1.5 hour, depending on the concentration of the gel) at the bottom of the gel chamber.
Electroblotting Protein to PVDF Membrane
11. Prior to the end of the electrophoresis prepare 3 containers. Fill one with methanol, one with water and another with transfer buffer (store at 40C). Cut PVDF membrane to approximate size of the gel and immerse in methanol for few seconds. Remove from this container to one with water for a further few seconds and finally remove to container of transfer buffer. Also put into transfer buffer container 2 sponges and 4 pieces of blotting paper to soak.
12. Prepare the sandwich by opening the sandwich case (black and white plastic contraption) and first putting on the sponges, one on each side. Squeeze out excess buffer from the sponges before doing so. Next, put 2 pieces of blotting paper on each sponge. Finally remove the membrane from the buffer and put this on the blotting paper. Cut the membrane to fit the sandwich if necessary. 
13. Remove the gel plate from the gel tank, remove the tape holding the gel plate together and immerse in transfer buffer to separate the plastic from its glass backing. The gel should stick to either one of the glass or the plastic once they are separated. Once separated, transfer the gel to the PVDF membrane and close sandwich case. Insert the case into the sandwich holder, the black side facing the red end of holder, and empty tank of the running buffer and replace it with Transfer Buffer. If Transfer Buffer is not enough it may be completed with methanol and water from the tanks in which the membrane was soaked before. Insert the sandwich in its holder into the tank and transfer for 45 minutes at 90 V.
Membrane Blocking and Antibody Incubations
14. Once transferred, remove sandwich cases and open. Carefully remove the gel trying not to leave any remains of the gel on the membrane. Transfer the membrane to a 50 ml falcon tube ensuring that the side of the membrane that was in contact with the gel (protein side) faces to the inside the tube and is not touching the wall of the tube. The transfer buffer can be put back in its bottle and stored at 4˚C for use again.
15. Wash the membrane twice for 10 minutes each with 1X TBS-Tween (store at room temperature) (about 10-15 ml) on a roller. Decant fluid after each wash.
16. Prepare Blocking Buffer by measuring 2.5g of non-fat milk powder (store at room temperature) in 50 ml of 1X TBS-Tween (making 5%). Add 30-40 ml of this to the membrane and allow to block for 90 minutes on a roller (this prevents non-specific binding sites).
17. Remove Blocking Buffer and add 5 µl (depending on required dilution) of primary antibody (store at 40C) to 5 ml (i.e. 1:1000 dilution) of the remaining blocking buffer. Add this to the membrane and mix overnight at 40C on a roller. Depending on the antibody, this incubation step may be done also for 2 hours at room temperature.
18. Remove primary antibody mixture from the tube and wash 3 times  on a roller using 10-15 ml of TBS-Tween for 10 minutes each.
19. After washes add 1 µl (depending on required dilution) of secondary antibody (store at 40C) to 10 ml (i.e. 1:10,000 dilution) of Blocking Buffer and leave on a roller for 90 minutes.
20. Remove  antibody and perform another 3 washes on a roller with TBS-Tween for 10 minutes each. While doing washes remove the developing kit from storage at 4˚C for it to warm up to room temperature.
Detection of Proteins
21. Add 2 ml of ECL solution A and 50 µl of solution B (i.e. 40:1) to the tube with the washed membrane, and wrap with foil to shield it from light. Mix on a roller for 5 minutes.
22. Cut a piece of Saran wrap large enough to wrap the membrane in. Once the developing fluid has been on the membrane for 5 minutes, remove the fluid and carefully place the membrane, protein side down, on a smooth piece of Saran wrap. Fold excess wrap across the back of the membrane and smooth out any creases or air bubbles across the front of the membrane.   
23. Place the membrane protein side up in the developing cassette
24. Turn on red light and cut film to size. Place film over membrane carefully trying not to move its position once down. Close cassette and wait for 2 minutes (or number of minutes required). Open cassette and remove film carefully, trying not to move film across the membrane. Place the film, exposed side down in the processor and press the small button on the left hand side of the wall. Wait for film to develop with protein bands. Expose another film if required for a longer period of time.
Stripping PVDF Membrane and re-probing 
25. Take membrane out of cassette and put back into a 50 ml falcon with protein side facing in and do two washes on a roller with 10-15 ml TBS-Tween for 5 minutes each.
26. Then add 50 ml of Stripping Buffer to the Falcon. Leave for 30 minutes in a waterbath set to 500C.
27. Perform another two washes on a roller with 10-15 ml TBS-Tween for 5 minutes each.
28. The membrane is now ready for reprobing so repeat steps 16-24 with appropriate primary and secondary antibodies. 
Note: The membrane may be stripped several times although the sensitivity decreases with each subsequent strip. The stripped membrane may be stored in TBS-Tween at 4C prior to reprobing.

10.10. Endocannabinoid extraction (extraction step performed in our laboratory in London, mass spectrophotometry kindly performed by Prof. George Kunos and co-workers)
Procedure for anandamide (AEA), 2-arachidonoyl glycerol (2AG), tissue extractions:
(A) 50mM TRIS Buffer pH8, store at 0-4ºC
	(3.028g C4H11NO3 dissolved in 500ml H2O,
	adjust pH with HCl)
(B) Homogenization Buffer, store at 0-4ºC
	1:1 mix of methanol (MeOH)  and (A) TRIS buffer. 	 
(C) Extraction solvent, store at –20ºC
	2:1 mix of Chloroform and MeOH
(D) Chloroform, store at –20ºC
(E) Internal Standard (IS d4-AEA): Reconstituted in cold MeOH and store at –80ºC (before preparation of solution (F) allow to warm-up to room temperature for accurate measurement in preparation of the working IS.)
(F) Working Internal Standard Mix: For each tissue sample, add 7µl of (E)d4-AEA to 0.5 ml of (B). Prepare enough solution for all samples. The same solution may be used for several consecutive days if stored at 4ºC.
Example: add 70µl (E) d4-AEA to 5 ml of (B), vortex, and place on ice. This is enough Internal Standard mix for 8 samples plus 1 Blank extract. 

Procedure: 
When tissue extractions are performed also prepare an extracted Blank containing the d4-AEA, but no tissue. This Blank will be used to check the background from the solvents, and to determine if any apparent AEA, 2AG, OEA, or other contaminants are present as a result of the extraction procedure. 
Transfer the homogenated tissue into a 15 ml polypropylene tube, centrifuge tube, keep on wet ice.
Add 1ml (C) to homogenising tube, homogenize residue and add to the 15 ml tube.
Repeat step 5. 
Add 0.5 ml (A) to the sample tube, vortex thoroughly and place tube in wet ice. 
Centrifuge samples at 2000g at 0ºC for 3 minutes to form the aqueous and chloroform layers. 
Transfer the chloroform dlayer to another properly labeled tube (borosilicate 13mm x 100mm screw cap tubes with polypropylene caps or polypropylene tubes prerinsed with methanol)
Add 1 ml (D) chloroform to extraction tube, vortex, thoroughly, add another 1ml (D) chloroform, vortex, thoroughly and repeat steps 8 and 9, and combine the chloroform extracts. 
Evaporate chloroform under nitrogen at room temperature.  Dry to complete dryness, and store samples at –80ºC until shipment.; or preparation for LC/MSD 


10.11. Production of corticosterone and placebo pellet moulds (performed by Csabe Fekete and co-workers)
The Corticosterone pellet mould is used for forming pellets that are implanted in animals for experimental purposes.
Cavities: 4.5 x 4.5 x 5mm 
Number of cavities: 15 
Mould size: 44 x 68 x 6mm thick



Corticosterone pellets are made by melting cholesterol and corticosterone together, pouring the mixture into a mould and allowing the mixture to cool to a solid pellet.

Ingredients:
Corticosterone (Aldrich 86, 229-0 or Roussel Uclaf)
Cholesterol (Steraloids, Inc (Wilton, NH) C6760))
Small glass beakers (10-15 mL size)
Tongs
Glass pasteur transfer pipettes and pipette bulb
Bunsen burner
Mold (Pelco Corp, electron microscopy mold #106. #106A)
Scalpel and blades
Large forceps
Balance

The pellets are performed as follows:
1.	Combined mass of corticosterone and cholesterol should equal 1 gram for each "melt". For example, to make 20% corticosterone pellets, weigh out 200 mgs corticosterone and 800 mgs cholesterol. Transfer the cholesterol into the beaker and place the corticosterone on top of the cholesterol.  
2.	Put the bulb on your pipette, light the burner, and pick up the beaker (containing cholesterol and B) using the tongs with your non-dominant hand.
3.	With your dominant hand, flame the transfer pipette and move the pipette out of the flame, then flame the beaker by waving the beaker back and forth across the flame watching for the first signs of the cholesterol melting. Use the back and forth motion of flaming the baker to help swirl and mix the melting mixture.
4.	Don't let the mixture bubble or remove the beaker from the flame before the corticosterone is completely melted. Re-flame the pipette and draw up and expel the molten corticosterone mixture back into the beaker once or twice to insure the mix is homogeneous.
5.	Transfer the mix into the wells of the mould. 
6.	Allow the mix to solidify and remove the pellets by inverting and flexing the mold.
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